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GENOMIC META-ANALYSIS COMBINING MICROARRAY STUDIES
WITH CONFOUNDING CLINICAL VARIABLES: APPLICATION TO
DEPRESSION ANALYSIS
Xingbin Wang, PhD
University of Pittsburgh, 2011
Major depressive disorder (MDD) is a heterogeneous psychiatric illness with mostly un-
characterized pathology and is the fourth most common cause of disability according to
the World Health Organization (WHO) and has a signicant impact on public health in the
United States. To understand the genetics of MDD, we aim to develop eective meta-analysis
approaches to provide high-quality characterization of MDD related biomarkers and path-
ways with proper clinical variable adjustment. First, genomic meta-analysis in MDD faces
multiple unique diculties, such as weak expression signal of MDD, substantial clinical het-
erogeneity and small sample size. Given these obstacles, it is hard to identify consistent and
robust biomarkers in an individual study. To achieve a more accurate and robust detection
of dierentially expressed (DE) genes and pathways associated with MDD, we proposed a
statistical framework of meta-analysis for adjusting confounding variables (MetaACV). The
result showed that more MDD related biomarkers and pathways were detected that greatly
enhanced understanding of MDD neurobiology. Secondly, Meta-analysis has become popu-
lar in the biomedical research because it generally can increase statistical power and provide
validated conclusions. However, its result is often biased due to the heterogeneity. Meta-
regression has been a useful tool for exploring the source of heterogeneity among studies
in a meta-analysis. In this dissertation, we will explore the use of meta-regression in mi-
croarray meta-analysis. To account for heterogeneities introduced by study-specic features
such as sex, brain region and array platform in the meta-analysis of major depressive disorder
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(MDD) microarray studies, we extended the random eects model (REM) for genomic meta-
regression, combining eight MDD microarray studies. The result shows increased statistical
power to detect gender-dependent and brain-region-dependent biomarkers that traditional
meta-analysis methods cannot detect. The identied gender-dependent markers have pro-
vided new biological insights as to why females are more susceptible to MDD and the result
may lead to novel therapeutic targets. Finally, we present an open-source R package called
Meta-analysis for Dierential Expression analysis (MetaDE) which provides 12 commonly
used methods of meta-analysis. It is a friendly used software such that biologists implement
meta-analysis in their research.
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1.0 INTRODUCTION
Major depressive disorder (MDD) is a heterogeneous psychiatric illness with mostly un-
characterized pathology, contributs to death by suicide, and is the fourth most common
cause of disability according to the World Health Organization (WHO). To understand the
genetics of MDD, gene expression analysis is a eective approach to identify the biomarkers
associated with MDD. Dierentially expressed (DE) gene detection is one of the most com-
mon analyses in microarray data, which are generally comprised of three components: (1) the
gene expression data; (2) the outcome variable, such as disease status; and (3) patient-specic
covariates, including treatment history and additional clinical and demographic information.
The primary aim of many gene expression studies is to identify the DE genes by character-
izing the relationship between the rst two of these components, the gene expression and
the disease outcome. Thus, in the literature, most psychiatric disease-related microarray
studies of similar design did not carefully consider how these factors (the third component)
inuence the relationship between the gene expression and the disease status. Usually they
either ignored the clinical variables or applied simple linear regression to include all variables
in the model. Our results clearly show the limits to those two approaches. To our knowledge,
this is the rst study that systematically considers the critical elements in the data structure
in order to obtain more accurate DE gene and pathway detection. In addition, due to the
very weak expression signal of MDD, a substantial clinical heterogeneity and small sample
size, it is hard to identify consistent and robust biomarkers in an individual study. In this
dissertation, we aim to develop eective meta-analysis approaches to ll this gap and provide
high-quality characterization of MDD related biomarkers and pathways with proper clinical
variable adjustment.
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This dissertation is organized as follows: in Chapter 1, the concept of MDD is rst
described in section 1.1; then, the statistics used in individual analysis, meta-analysis and
pathway analysis methods are reviewed in sections 1.3,1.4 and 1.5, respectively. In chapter 2,
we describe a statistical approach for meta-analysis to tackle weak signal expression proles
that have small sample size, case-control paired design and confounding covariates in each
study. In Chapter 3, a meta-regression model with variable selection is described. In Chapter
4, the implementation and usage of the MetaDE package are described. Conclusions and
future works are provided in Chapter 5.
1.1 MAJOR DEPRESSIVE DISORDER
Major depressive disorder (MDD) is a mental disorder characterized by an all-encompassing
low mood accompanied by low self-esteem, and by loss of interest or pleasure in normally
enjoyable activities. MDD is a disabling condition which adversely aects a person's family,
work or school life, sleeping and eating habits, and general health[65]. It involves a minimum
two-week continuous period of at least ve of the following symptoms: lowered mood for
the majority of the day, diminished pleasure in daily activities, weight loss or gain, sleep
disturbance, agitation or lethargy, fatigue, feelings of worthlessness or helplessness, impaired
thought or memory, and recurring thoughts of self-harm or death (DSM-IV 2000). Depression
is a common human psychiatric disorder and the leading cause of disability in North America,
aicting an estimated 18% of the population with an approximate lifetime incidence of 12%
in men and 20% in women [55]. Around 3.4% of people with major depression commit
suicide, and up to 60% of people who committed suicide had depression or another mood
disorder. The symptoms of depression are the greatest contributor to the global burden of
disease [46] as calculated by total days lived with the disorder. It remains the fourth leading
cause of worldwide disability, after accounting for higher mortality in other diseases. This
ranking is expected to rise to second place by the year 2020, as current eective treatment
for other diseases become more globally accessible.
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Risk factors for depression: Major risk factors for depression include the sex of an in-
dividual, previous history of the illness, genetic predisposition/family history, and chronic
or acute stress [30]. Some combination of these can prompt a depressive episode, but the
requisite combination varies by individual. The threshold for depression is sensitive to social
support, religiosity, age, and life stressors [14, 56, 57]. These environmental factors interact
with the genetics of depression estimated at 33% heritance [30]. This is a lower heritability
than bipolar disorder, or schizophrenia, which adds to the diculty in teasing apart con-
tributory factors. Depression itself is a risk factor for the disorder, as untreated depression
is likely to reoccur [70]. This is particularly problematic as a signicant percentage of pa-
tients (varying from placebo levels of 30%, up to 40% depending on the study) never meet
the criteria for complete remission and will commonly endure increasingly lengthy bouts of
depression [36, 58].
Complexity obscure the neuropathology of depression: Depression's continued toll on
society is a function of multiple genetic and environmental susceptibilities that recruits a di-
verse cadre of further genetic factors to sustain the condition [6]. To date, most experiments
have examined single aspects of the disease, but the complex causal factors in depression
make it resistant to highly specic approaches. One immediate question is: Why not cre-
ate sub-divisions of depression that have more homogeneous symptom groups that will be
amenable to a pathology classication? However, clinical evidence does not strongly support
this approach. In patients with repeated depressive episodes there is no correspondence of
symptoms across episodes, preventing denitive clinical subdivisions that might have more
consistent pathophysiology[74]. There is some evidence to suggest that classes of antidepres-
sants have distinct response rates in dierent DSM-IV classications of depression (atypical,
psychotic, bipolar etc) [4]. However, a meta-analysis of over 100 antidepressant drugs trials
found no dierence in response rates as an interaction of drug class and putative subtype[17].
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Table 1.1: Data description of eight MDD microarray studies
Study Gender Brain region sample Platform
MD1 ACC M ACC 32(16) Aymetrix
MD3 ACC F ACC 44(22) Illumina
C MD2 ACC F ACC 18(9) Illumina
C MD2 ACC M ACC 26(13) Aymetrix
MD1 AMY M AMY 28(14) Illumina
MD3 AMY F AMY 42(21) Illumina
C MD2 DLPFC F DLPFC 28(14) Aymetrix
C MD2 DLPFC M DLPFC 32(16) Aymetrix
1.2 DATA DESCRIPTION AND PROBLEMS ENCOUNTERED IN GENE
EXPRESSION ANALYSIS
Data description In this dissertation, we will focus on 8 human studies listed in Table 1.1
obtained from Dr. Sibille's lab for meta-analysis. In most of the patient cohorts, MDD
patients are matched to control patients by their demographics such as age, sex and race.
MDD related clinical variables of the patients are available for most studies, including alcohol
consumption (AH), history of taking anti-depressant drugs (AD), death by suicide (SC), pH
level of brain tissues (pH), disease recurrence (RC) and postmortem interval (PMI). Each
study has three study-level features that may need adjustment in the analysis: sex, brain
region, and array platform.
Problems encountered in gene expression analysis: Detecting candidate markers in tran-
scriptomic studies is often dicult in MDD studies: First, as described in section 1.1, MDD
is thought to be a complex and heterogeneous disease, associated with multiple genetic,
genomic, post-translational, and environmental factors. Furthermore, patients might have
varying disease severity, with some having psychotic features as well as exposure to a variety
of medications and dosage levels to control their illness. Secondly, the genetic disease eects
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are potentially confounded by many covariates, which include (1) demographical variables
such as age, sex and race; (2) clinical variables such as anti-depressant drug usage, death by
suicide and alcohol dependence; (3) technical variables inherent in the use of post-mortem
brain samples, such as the pH level of brain tissues, brain region and post-mortem interval
(PMI). If the statistical models employed to identify dierentially expressed genes fail to
incorporate these sources of heterogeneity, not only can this reduce the statistical power, but
also it will introduce sources of spurious signals to the gene detection. Finally, sample sizes
for these studies are generally small (between 9-22 pairs of MDDs and controls) due to the
limited availability of suitable brain specimens and the signicant costs associated with their
collection. These three features in MDD studies severely hamper accurate biomarker detec-
tion. In section 1.3, we listed several statistical methods often used in the literature for DE
gene detection in individual analysis, such as paired or unpaired t-test or the simple linear
regression model. The former approach undoubtedly ignored the eects from confounding
covariates; the latter approach was not ecient or not even applicable when the number of
covariates is large and the number of samples in each study is small. These methods have
been shown to have low statistical power in each MDD study with weak signal expression
proles, small sample size, case-control paired design and confounding covariates.
1.3 EXISTING METHODS FOR DE GENE DETECTION IN SINGLE
STUDY
Gene-expression microarrays hold tremendous promise for revealing the patterns of coor-
dinately regulated genes. Because of the large volume and intrinsic variation of the data
obtained in each microarray experiment, statistical methods has been used as a way to sys-
tematically extract biological information and to assess the associated uncertainty. SAM
and LIMMA are popular methods for microarray. Methods we covered here are more naive
versions.
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1.3.1 T-TEST
The t test perhaps is the most popular method for detecting dierentially expressed genes
due to its simplicity and availability. The t statistic is dened as
Tg =
YD   YC
S
q
1
nD
+ 1
nC
; (1.1)
where YD and YC are the mean values of disease (MDD) and control groups; nD and nC are
the number of replicates in disease and control groups. S is the pooled standard deviation,
which is estimated by S =
q
(nD 1)S2D+(nC 1)S2C
nD+nC 2 . Under normal assumption, Tg follows a
central student's t distribution with degree of freedom nC + nC   2 under null hypothesis
if we assume that MDD and control group have the same variance and the experiment was
not pair-designed.
1.3.2 Paired T-TEST
The matched groups design is another popular form in medicine research in which subjects
from disease and control groups are matched on some demographic variables such as age,
gender and race. In this situation, paired t-test is the conventionally used test, which is
dened as,
Tg =
YD   YC
S
q
1
n
; (1.2)
where S is the standard deviation of dierences of each pair, which is estimated by S =qPn
i=1[(YDi YCi) ( YD  YC)]2
(n 1) . Tg follows Student's t distribution with degree of freedom of n 
1 under assumptions that the paired dierences are independent and identically normally
distributed. In general, paired test has more power than unpaired test whenever the within-
pairs covariance is positive. Note that an alternative to the paired Student's t-test when
the population can not be assumed to be normally distributed is the Wilcoxon singed-rank
test[102].
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1.3.3 MODERATED T-TEST
The gene-specic t test is not aected by heterogeneity in variance across genes because it
only uses information from one gene at a time. It may, however, have low power because
the sample size is small. In addition, the variances estimated from each gene are not stable:
for example, if the estimated variance for one gene is small, by chance, the Tg value can be
large even when the corresponding mean dierence is small. To account for gene-specic
uctuations, a moderated t statistics [27, 99] is dened as below,
Tg =
YD   YC
sg + s0
; (1.3)
where YD and YC are the mean values of expression for gene g in disease and control
groups, respectively; sg is the standard deviation of repeated expression measurements:sg =r
[(nD 1)S2D+(nC 1)S2C ][ 1nD+
1
nC
]
nD+nC 2 ; s0 is a positive constant to minimize the variability among
sg(1  g  G). In SAM, a regression procedure was used to select the optimal value of s0.
For simplicity, s0 was often selected as the median of sg. With this modication, genes with
small mean dierences will not be selected as signicant, and this removes the problem of
stability mentioned above.
1.3.4 LINEAR REGRESSION MODEL
A simple linear regression model[67, 76] has been commonly used to detect DE genes to
account for additional variability resulting from many confounding variables. (e.g., in MDD
studies, Age, pH, PMI and RIN). The model is described as below:
Ygi = g + g0X0i +
LX
l=1
glXli + gi; (1.4)
In the model, Ygi was the gene expression value of gene g( g  G) and sample i . X0i
was the disease label that took value one if the sample was disease and zero if sample was a
control. Xli represented values for potential confounding covariate l (1  l  L); 0-1 binary
for categorical variables of two levels and numerical for continuous variables). Finally, gi
were independent random noises that followed a normal distribution with mean zero and
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variance 2g . Under this model, g0 was the disease eect of gene g and was the parameter
of major interest. To obtain a disease-associated biomarker candidate list in a single study
analysis, likelihood ratio test (LRT) or wald test was used to assess the p-values of testing
H0 : g0 = 0 (vs HA : g0 6= 0).
1.4 EXISTING MICROARRAY META-ANALYSIS METHODS
Many high-throughput genomic technologies have advanced dramatically in the past decade.
Microarray experiment is one example that evolved into relative maturity with general con-
sensus experimental protocol and data analysis strategy. Its extensive application in the
biomedical eld has led to an explosion of gene expression proling studies publicly avail-
able. The noisy nature and small sample size in each dataset, however, often result in
inconsistent biological conclusions. Consequently, meta-analysis methods for combining mi-
croarray studies have been widely applied to increase statistical power and provide validated
conclusions. Four major categories of statistical methods have been used to combine microar-
ray studies in dierentially expressed (DE) gene detection: combining p-values, combining
eect sizes, combining ranks and directly merge after normalization. In this dissertation,
we mainly focused on the rst two categories, one is to combine statistical signicance (p-
value)[52, 79, 80] from each individual study, and the other is to combine the eect sizes
[15, 66]from each individual study. In general, among these microarray meta-analysis meth-
ods used in the literature, most methods have their pros and cons depending on the data
structure and biological goal [47, 78]. Briey, methods based on combining p-values are free
of distribution assumptions and more powerful when the studies combined are heterogeneous,
but do not support inferences about magnitudes and directions. On the other hand, meth-
ods based on combining eect sizes provide information about magnitudes and directions
(e.g. down-regulated or up-regulated), but are more stringent on assumptions. In section
1.4.1, we described several representative methodologies for the rst category. The represen-
tative methodologies for the second category were described in section 1.4.2. In these two
sections, we consider K independent experiments have been performed to detect a certain
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eect, gk is the parameter that characterizes the condition (e.g. disease) eect in study
k; k = 1; 2;    ; K for gene g; (1  g  G). The kth experiment is concerned to test the
hypothesis H0gk : gk = 0 against an alternative H1gk : gk 6= 0, and the p-value associated
with the above test is denoted as pgk.
1.4.1 METHODS COMBINING P-VALUES
1.4.1.1 Fisher's method(Fisher) Fisher's method (Fisher)[31, 32]is perhaps the most
widely used combination procedure, which uses the product of p-values from tests in each
study and transform it to chi-square scores using  2 log transformation.
V Fisherg =  2
KX
k=1
log(pgk) (1.5)
Under the null hypothesis, statistics V Fisherg follows a 
2 distribution with 2K degrees of
freedom. This method aggregates statistical signicance from each study and generally has
good detection power. It, however, can detect genes that are extremely signicant (e.g.
p=1E-20) in one study but not signicant in the other four studies, a set of genes normally
of less biological interests. See Li and Tseng [52] for more discussion.
1.4.1.2 Tippett's method(minP) This method is called minimum p-value (minP)
method proposed by Tippett [82].
V minPg = min
1kK
pgk (1.6)
Under the null hypothesis, V minPg has a Beta distribution with degrees of freedom 1 and K.
This method is also viewed as the union-intersection method. Say the rejection region for
the test of H0gk is fpgk  g, where  is the overall signicance level. Like Fisher's method,
this method is also sensitive to very small p values in partial studies, but it is less powerful
than Fisher's approach.
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1.4.1.3 Wilkinson's Method(maxP) Maximum p-value(maxP) is a special case pro-
posed by Wilkinson[103].
V maxPg = max
1kK
pgk (1.7)
Under the null hypothesis, V maxPg has a Beta distribution with degrees of freedom K and 1.
In contrast to Fisher's method, maxP detects genes that have small p-values in all studies
but is usually less powerful than Fisher's method.
1.4.1.4 Generalized ordered statistics(rOp) maxP method is very conservative in
that it requires all genes dierentially expressed in all studies. A robust alternative is to
apply the r-th ordered p-value ( rOp). Let pg(r) denote the rth order statistic of K p-values,
pg1; pg2;    ; pgK .
V ropg = pg(r) (1.8)
Under the null hypothesis, V ropg has a Beta distribution with degrees of freedom r and
K   r + 1. The r-th ordered p-value method (rOP) provides an alternative approach with
robustness when large numbers of studies with potentially heterogeneous patient cohorts and
variable quality are combined.
1.4.1.5 Stouer's Method(Stou) Stouer's method is also called the inverse normal
method proposed by Stouer [90]. This procedure involves transforming each p-value to the
corresponding normal score. and then taking the average. More specically, dene Zk by
pk = (Zk), where (x) is the standard normal cumulative distribution function. Then
Stouer's test statistic is dened as,
V Stuof =
PK
k=1
 1(pk)p
K
; (1.9)
Under null hypothesis, V Stuof has the standard normal distribution. A weighted inverse
normal method was generalized by Mosteller and Bush[69] to give dierent weights to each
study according to their power. The weighted inverse normal test statistic is dened as
V W Stuof =
PK
k=1wk
 1(pk)qPK
k=1w
2
k
; (1.10)
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Under null hypothesis, V w Stouff also has the standard normal distribution. Whitlock [101]
suggests that the weights can be chosen to be the inverse of squared standard error. He
further shows weighted method is superior to the un-weighted version.
1.4.1.6 Adaptively weighted Fisher's Method(AW) Li and Tseng[52] elucidated
two statistical hypothesis settings behind two separate biological goals in combining mul-
tiple array studies and developed an adaptively-weighted (AW) method. Genes that are
dierentially expressed in all studies were termed as HSA type (hypothesis setting A) while
genes dierentially expressed in at least one study was called HSB type. The adaptively-
weighted statistic is dened as:
Ug(wg) =  
KX
k=1
wgk log(pgk); (1.11)
V AWg = min
wg2W
pU(g(wg)); (1.12)
,where wg = (wg1; wg2;    ; wgK), and g(w) is the observed statistic for Ug(w), and W =
fwjwi 2 f0; 1gg. Because the exact distribution of AW statistic can not be derived analyti-
cally, the p-value is usually calculated by permutation method. It has been shown that AW
method has the power to identify DE genes considered signicant in either partial or full data
sets, and the resulting weight provides a natural categorization of the detected biomarkers
for further biological investigation.
1.4.2 METHODS COMBINING EFFECT SIZES
The eect size (ES) reects the magnitude of the disease eect or (more generally) the
strength of association with clinical outcome and was widely used to combine information in
meta-analysis. There are many dierent metrics that can be used to measure eect size,such
as the r statistics(correlation coecients)[81], d statistics[20, 44] and the odds ratio (OR)[35].
Here, we mainly focus on the d statistics proposed by Hegdes [44].Specically,denote the
gene expression value of gene g(1  g  G) in the disease (D) and control(C) groups of pair
i(1  i  nk) and study k(1  k  K) by Xdgki and Y Cgki, respectively. We assume that these
studies are independent and that each of the XDgki and Y
C
gki is normally distributed. More
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succinctly, XDgki  N (dgk; 2gk) and Y Cgki  N (cgk; 2gk), (1  g  G; 1  i  nk; 1  k  K).
The eect size parameter gk for gene g in kth study is dened as
gk =
dgk   cgk
gk
; k = 1; 2;    ; K (1.13)
To estimate the population eect size, the d statistic for standardized eect size mea-
sures is often used in the literature [15, 44]; however, it is a biased estimator of the pop-
ulation eect size(gk), and underestimate when the sample size is relatively small. Thus,
an unbiased estimator, d
0
, is alternatively developed by multiplying a correction factor,
c(m) =  (m=2)p
m=2 ((m 1)=2) , in [66, 26], where  (x) is the Gamma function and m is the degree
of freedom of d statistics. Below, we show detailed formulation to estimate gk from studies
that are unpaired or paired design.
Computing d and d
0
from studies that are unpaired design: We can estimate the stan-
dardized mean dierence (gk)from studies that are unpaired design with two independent
samples as:
d =
YD   YD
Sp
(1.14)
where YD and YC are the sample means in the disease and control group, respectively. In the
denominator, Sp is the pooled standard deviation across groups, Sp =
q
(nD 1)S2D (nC 1)S2C
nD+nC 2 ,where,
SD and SC are the sample standard deviations in disease and control group, respectively.
The estimator of the variance of d is given in [15, 44]
V ar(d) =
nDnC
nD + nC
+
d2
2(nD + nC)
(1.15)
, which is an asymptotic estimator. Then, the exact form of the variance is provided by
Hedges[43] and used by Marot [66], it can be shown that
V ar(d) =
m
(m  2)~n [1 + ~nd
2]  d
2
c2(m)
(1.16)
, where ~n = nDnC
nD+nC
,and m = nD + nC   2.
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Correspondingly, the d
0
statistic and its variance is given by,
d
0
= c(m)d (1.17)
V ar(d
0
) = c2(m)V ar(d): (1.18)
Computing d and d
0
from studies that are paired design: While the studies are paired
design with matched groups, the standardized mean dierence (gk)from studies can be
estimated by :
d =
YD   YD
Sp
; (1.19)
where YD and YC are the sample means in the disease and control group, respectively. In the
denominator, Sp is the pooled standard deviation across groups, Sp =
p
S2D + S
2
C   2SDSCr,where,
SD and SC are the sample standard deviations in disease and control group, respectively,and
r is the sample correlation coecient, r =
Pn
i=1(YiD  YD)(YiC  YC)
SDSC
. The estimator of the variance
of d is given in [9, 26]
V ar(d) =
2(1  r)
n
+
d2
2(n  1) (1.20)
, which is an asymptotic estimator. Then, the exact form of the variance is provided by
Becker [9] and corrected by Morris [68], it can be shown that
V ar(d) =
2(1  r)
n
(
n  1
n  3)[1 +
nd2
2(1  r) ] 
d2
c2(n  1) (1.21)
, where n is the sample size in each group.
Correspondingly, the d
0
statistic and its variance is given by,
d
0
= c(m)d (1.22)
V ar(d
0
) = c2(m)V ar(d): (1.23)
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1.4.2.1 Fixed Eects model(FEM) Fixed eects model is an often-used method of
combining eect sizes when the studies to be combined are homogeneous, in which only
within-study variability is considered. The assumption is that studies use identical methods,
samples, and measurements; that they should produce identical results; and that dierences
are only due to within-study variation. The general model is given by
Ygk = g + gk: (1.24)
Under the xed-eect model we assume that there is one true eect size which underlies all
the studies in the analysis, and that all dierences in observed eects are due to sampling
error. Thus Ygk  N(g; 2gk). The most ecient and unbiased estimator of 1 is the weighted
average of estimates where the weight is determined by inverse of their standard errors. The
estimate is
^g =
PK
k=1wgkYgkPK
k=1wgk
; (1.25)
where wgk = S
 2
gk and S
2
gk s the estimated within-study variance in study k for gene g. The
variance of ^g is then
V ar(^g) =
1PK
k=1wgk
: (1.26)
So, a Z-score to test the null hypothesis that the common true eect g is zero can be
computed using
ZFEMg =
^gp
V ar(^g)
: (1.27)
which follows a standard normal distribution.
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1.4.2.2 Random Eects model (REM) REM method is a popular method for comb-
ing eect sizes in meta-analysis, which makes the assumption that individual studies are
estimating dierent treatment eects. Choi et al [15] were probably among the rst authors
to raise this issue of meta-analysis in the context of microarray data to nd DE genes using
this method, where the eect size is dened as the standardized mean dierence d =
YD  YC
Sp
,
where YD and YC represent the means of disease (MDD) and control groups, respectively,
and Sp indicates an estimation the pooled variation. The corresponding model used was
described as:
Ygk = g + gk + gk; (1.28)
where Ygk is the observed eect size in study k for gene g; the parameters gk and gk
are the between-study and within-study errors, respectively. It assumeshin-study variances,
respectively. Usually, the estimate of 2gk can be produced in each study k. The between-
study variance can be estimated using a method of weighted moments (MM) estimator of
 2g , which can be derived from the heterogeneity statistic Qg =
PK
k=1wgk(Ygk   ^g)2, where
^g = (
PK
k=1wgkYgk)=
PK
k=1wgk is the feasible weighted least-squares estimator with weights
wgk = s
 2
gk , and s
 2
gk is the estimate of 
2
gk. Then, the weighted unbiased MM estimator of 
2
g
suggested by DerSimonian and Larird (DL)[22]: ^ 2g = maxf0; Q (K 1)s1 (s2=s1)g, where wgk = s 2gk ,
and sr = w
r
gk(r = 1; 2), and K is the number of studies. Under the assumption that the gene
expression levels were normally distributed, a z-score to test for DE genes was constructed as,
ZREMg =
^(g)p
V ar(^(g))
, which follows a normal distribution with zero mean and unit variance.
The p-values of each gene could then be calculated and subsequent inferences could be made.
1.4.2.3 Fixed eects model versus Random eects model When we perform a
meta-analysis using a xed eects model or random eects model, one of rst decisions we
have to make is "Which model is more appropriate for current data?". The selection of a
computational model should be based on our expectation about whether or not the studies
share a common eect size and on our goals in performing the analysis. It makes sense to
use the xed eects model if we believe that all the studies included in the analysis are func-
tionally identical. By contrast, when the data sets are accumulated from a series of studies
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that had been performed by researchers operating independently, it would be unlikely that
all the studies were functionally equivalent. Typically, the subjects or interventions in these
studies would have diered in ways that would have impacted the results, and therefore we
should not assume a common eect size. Therefore, in these cases the random eects model
is more easily justied than the xed-eect model. Therefore, a random eects model may
be more general, in which both the random variation within the studies and the variation
between the dierent studies is incorporated. However, more data are required for random
eects models to achieve the same statistical power as xed eects models. Testing how
much heterogeneity there is is a way to determine whether the xed eects model or random
eects model is appropriate.Heterogeneity in meta-analysis refers to the variation in study
outcomes between studies.
In practice, the question of which model is appropriate for given studies can be addressed
by testing for the homogeneity of study eects. There are some general ways to assess hetero-
geneity in meta-analysis, but each has a liability for interpretation. In this dissertation, we
focused on the one now widely-used chi-squared test (a Q-statistic) proposed by Cochran[8].
The Q statistic is dened as Qg =
PK
k=1wgk(Ygk ^g)2, where ^g = (
PK
k=1wgkYgk)=
PK
k=1wgk
is the feasible weighted least-squares estimator with weights wgk = s
 2
gk , and s
 2
gk is the esti-
mate of 2gk. Under the hypothesis of homogeneity, it follows a 
2
K 1 distribution. A large
observed value of the statistic Q relative to this distribution indicates rejection of the hy-
pothesis of homogeneity, which therefore a random eect model is more appropriate. The
previous method is based on gene by gene test. To further conrm the existence of the
heterogeneities, we assume that the genes can be treated as independent samplings and the
homogeneity can be explored over all the genes. The histogram of the observed Q values and
quantile-quantile plots (Q-Q plot) of the observed versus expected values are used conrm
the existence of the heterogeneity overall.
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1.5 PATHWAY ENRICHMENT ANALYSIS
In above sections, meta-analysis methods that combine gene expression information across
studies were reviewed. Gene expression information can be also integrated within a study.
Specically, instead of studying each gene individually, we can also study a gene set. A
gene set is a pre-dened set of genes that may have similar locations or functions or form a
particular pathway. If genes in a gene set act in concert, this gene set may have important
biological eects on the phenotype of concern [91]. Thus, it is important to test whether a
set of genes is coherently associated with the phenotype of interest. This type of analysis is
called gene set enrichment analysis or pathway enrichment analysis[73, 91, 96]. When gene
sets are dened by biological pathways, the term gene set enrichment analysis and pathway
enrichment analysis are interchangeable. The common gene set/pathway databases include
KEGG, Biocarta, and the gene ontology (GO) databases [37, 54]. The molecular signatures
database (MsigDB) [91] is a collection of gene sets (including KEGG, Biocarta and GO) that
has ve major categories, including C1: positional gene sets; C2: curated gene sets; C3: motif
gene sets; C4: computational gene sets and C5: GO gene sets. In this dissertation, pathway
enrichment analysis was mainly used to evaluate the ndings in in individual analyses and
meta-analyses.
In the following sections, we give a brief review of two most commonly used pathway
enrichment methods. Fisher's exact test is described in Section 1.5.1, and Kolmogorov-
Smirnov (KS) test is described in Section 1.5.2.
1.5.1 Fisher's Exact Test
The Fisher's exact test method has been widely used in pathway enrichment analysis as
a result of its simplicity[12, 24, 25, 106, 108]. The purpose for Fisher's exact test in this
study was to determine whether the ratio of DE genes in a gene set was higher than the
ratio outside of the pathway. If the ratio was higher than would be expected by chance, the
pathway was referred to as an enriched pathway. The rst step in Fisher's exact test method
was to identify DE genes, the number of DE genes both inside and outside of the pathway
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Table 1.2: 2 2 Contingency Table for Pathway Enrichment Analysis
In pathway out of pathway Total
DE c l-c l
Non-DE t-c G-l-t+c G-l
Total t G-t G
was then counted as a 2  2 contingency Table (Table 1.2). The p-value for enrichment
of a pathway was calculated by testing the independence of the 2  2 contingency Table
using Fisher's exact test. The null and alternative hypothesis for the Fisher's exact test is:
H0 : p1 = p2 and Ha : p1 > p2, where p1 and p2 are the probability of DE genes inside and
outside of the pathway. In the Fisher's exact test, suppose a total number of G genes in the
genome were considered, among them t genes were in the pathway, l genes were contained
in the biomarker list and c genes were common to the target pathway (gene set) and the
biomarker list (shown in Table 1.2). The p-value of the pathway enrichment was calculated
from a hypergeometric distribution by p =
Pmin(l;t)
x=c
 
t
x
 
G t
l c

=
 
G
l

.
1.5.2 Kolmogorov-Smirnov (KS) Test
The Kolmogorov-Smirnov test (KS test) is a nonparametric test for the equality of contin-
uous, one-dimensional probability distributions that can be used to compare a sample with
a reference probability distribution (one-sample KS test), or to compare two samples (two-
sample KS test). The two-sample KS test is one of the most useful and general nonparametric
methods for comparing two samples, as it is sensitive to dierences in both location and shape
of the empirical cumulative distribution functions of the two samples, so it was widely used
in pathway enrichment analysis[91, 61]. Specically, the p-values calculated from individual
analyses or meta-analyises for assessing the DE genes are classied into two categories, in the
pathways (P ) and out of pathway (PC). Let p(1); p(2);    ; p(n) and ~p(1); ~p(2);    ; ~p(m) denote
the order statistics of the p-values in P and PC , respectively. The corresponding empirical
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distribution functions, F^P (x) and F^PC (x) for P and P
C can be dened as:
F^P (x) =
8>>>>><>>>>>:
0; if x < p(1)
k=n; p(k)  x < p(k+1) for k = 1; 2;    ; n  1
1; if x  p(n)
and
F^PC (x) =
8>>>>><>>>>>:
0; if x < ~p(1)
k=m; ~p(k)  x < ~p(k+1) for k = 1; 2;    ;m  1
1; if x  ~p(m)
Let FP and FPC denote the population distribution for P and P
C , respectively. The one-sided
two sample KS test can be dened based on the formula:
TKS = sup
x
(FP (x)  FPC (x)) (1.29)
in which the null hypothesis and the alternative hypothesis are:
H0 : FP (x) = FPC (x) for all X (1.30)
Ha : FP (x)  FFC (x) for all x (1.31)
FP (x) > FPC (x) for some x (1.32)
Under the null hypothesis, the rejection region has the form of TKS > K at level of .
Rejection of H0 means that P is stochastically less than P
C (the CDF of P lies above and
hence to the left of that for PC). In other words, the p-values of genes in the pathway P
are stochastically less than the p-values of genes outside of pathway PC . This indicates that
genes in the pathway P have a stronger association with phenotype than genes from outside
of the pathway PC ; thus, the pathway is of interest. Small p-value associated with KS test
indicates a good performance of the methods.
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2.0 A SYSTEMATIC STATISTICAL APPROACH TO INTEGRATE
WEAK-SIGNAL MICROARRAY STUDIES ADJUSTED FOR
CONFOUNDING VARIABLES WITH APPLICATION TO MAJOR
DEPRESSIVE DISORDER
2.1 MOTIVATIONS
Microarray technology enables researchers to examine the expression of thousands of genes
in parallel. Dierentially expressed (DE) gene detection is one of the most common anal-
yses in microarray data. In such an analysis, genes dierentially expressed under multiple
conditions are detected and are used for generating further biological hypotheses, developing
potential diagnostic tools, or investigating therapeutic targets. The extensive applications of
microarray technology have led to an explosion of gene expression proling studies publicly
available. However, the noisy nature of microarray data, together with small sample size
in each study, often results in inconsistent biological conclusions [28, 92, 107]. Therefore,
meta-analysis, a set of statistical techniques to combine multiple studies under related re-
search hypotheses, has been widely applied to microarray analysis to increase the reliability
and robustness of results from individual studies. In the literature, three major categories of
meta-analysis methods have been applied to genomic meta-analysis: combining eect sizes
[15, 66] , combining p-values [52, 79, 80] and combining rank statistics [21, 48]. In general,
dierent approaches have dierent underlying assumptions and pros and cons in the appli-
cation [78]. Major depressive disorder is a heterogeneous illness with mostly uncharacterized
pathology. Despite many gene expression studies of MDD [3, 53, 85, 88, 87] published, the
biological mechanisms of MDD remain mostly uncharacterized [7]. Although biomarkers
and pathways have been identied in specic studies, the ndings are not consistently ob-
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served from study to study. This variability may be due to several factors. Firstly, MDD is
thought to be a complex and heterogeneous disease [72], associated with multiple genetic,
genomic, post-translational, and environmental factors. Furthermore, patients might have
varying disease severity, with some having psychotic features as well as exposure to a variety
of medications and dosage levels to control their illness. Secondly, the genetic disease eects
are potentially confounded by many covariates, which include (1) demographical variables
such as age, gender and race; (2) clinical variables such as anti-depressant drug usage, sui-
cide and alcohol consumption; (3) technical variables inherent in the use of post-mortem
brain samples, such as the pH level of brain tissues, brain region and postmortem interval
(PMI). If the statistical models employed to identify dierentially expressed genes fail to
incorporate these sources of heterogeneity, not only can this reduce the statistical power,
but also it will introduce sources of spurious signals to the gene detection. Finally, sample
sizes for these studies are generally small (between 10-25 pairs of MDDs and controls) due
to the limited availability of suitable brain specimens and the signicant costs associated
with their collection. In this paper, we propose a statistical framework to tackle weak signal
expression proles that have small sample size, case-control paired design and confounding
covariates in each study. We use a set of ve major depressive disorder (MDD) expression
proles as an illustrative example. In the literature, most analyses of similar data struc-
ture either ignored the potentially confounding covariates by using paired or unpaired t-test
[18, 51, 98] or applied simple linear regression model to incorporate all covariates [67, 76].
The former approach undoubtedly ignored eects from confounding covariates; the latter
approach was not ecient or even not applicable when the number of covariates is large and
the number of samples in each study is small. In this paper, we will propose a framework
that uses a random intercept model (RIM) to account for the case-control paired design and
confounding covariates in single study analysis. An improved RIM with gene-specic vari-
able selection (namely RIM minP or RIM BIC to be introduced later) will be performed to
accommodate the small sample size and relatively large number of covariates in individual
studies. We will then apply and compare three popular meta-analysis methods: Fisher's
method [31, 32], inverse variance weighted random eects model [15, 44], and maximum p-
value method [50, 86, 103]. Our proposed framework is general and applicable in commonly
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Table 2.1: Data description of ve MDD microarray studies
Study Gender Brain region sample Platform
MD1 ACC M ACC 32(16) Aymetrix
MD2 ACC M ACC 20(10) Illumina
MD3 ACC F ACC 50(25) Illumina
MD1 AMY M AMY 28(14) Aymetrix
MD3 AMY F AMY 42(21) Illumina
encountered microarray meta-analysis of complex genetic diseases. Simulations considering
various correlation structures among disease state, gene expression and covariates will be
performed to demonstrate the better performance of this framework. The application of
combining ve MDD microarray studies also show improved DE gene detection power and
superior statistical signicance of pathway detection using our proposed method.
2.2 MATERIALS
Description of motivating MDD data: This research is motivated from the meta-analysis
of combining ve MDD transcriptomic studies. Brain tissues of three patient cohorts (MD1,
MD2 and MD3) obtained from dierent sources at dierent time were analyzed. For all
three patient cohorts, tissues from the anterior cingulated cortex (ACC) brain region were
analyzed by microarray experiments independently to generate three microarray studies:
MD1 ACC, MD2 ACC and MD3 ACC. Similarly, tissues from the amygdala (AMY) brain
region in MD1 and MD3 cohorts were analyzed to generate MD1 AMY and MD3 AMY.
Details of the ve patient cohorts and microarray studies are available in Table 2.1. In each
patient cohort, MDD patients were matched to control patients by three demographic vari-
ables: age, sex and race. Three additional clinical variables (alcohol consumption, history
of taking anti-depressant drugs and history of committing suicide) and two technical vari-
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Table 2.2: Pearson correlation between covariates in three MDD cohorts (collinearity evaluation)
Age Alcohol Antidep Suicide pH PMI
Age | (-0.05, 0.34, 0) (0.15, 0.14, 0.04) (0.02, -0.26, 0) (-0.12, -0.01, -0.04) (-0.19, -0.17, 0.37)
Alcohol (-0.05, 0.34, 0) | (-0.21, 0.63, 0.28) (0.41, 0.15, 0.22) (0.09, 0.22, -0.08) (-0.02, -0.29, -0.04)
Antidep (0.15, 0.14, 0.04) (-0.21, 0.63, 0.28) | (0.31, 0.19,0.22) (0.18, 0.36,-0.21) (-0.13, -0.35, -0.18)
Suicide (0.02, -0.26, 0) (0.41, 0.15, 0.22) (0.31, 0.19,0.22) | (0.19, -0.3, 0.06) (-0.17, -0.38, -0.02
pH (-0.12, -0.01, -0.04) (0.09, 0.22, -0.08) (0.18, 0.36,-0.21) (0.19, -0.3, 0.06) | (0.41, -0.03, -0.03)
PMI (-0.19, -0.17, 0.37) (-0.02, -0.29, -0.04) (-0.13, -0.35, -0.18) (-0.17, -0.38, -0.02) (0.41, -0.03, -0.03) |
ables (pH level of brain tissues and post-mortem interval PMI) were also available for each
patient. Among the covariates described above, six variables (age, alcohol, drug, suicide, pH
and PMI) are considered potential confounders in the DE gene detection of MDD. These six
covariates were not highly correlated in our analysis and thus the collinearity issue does not
exist in the linear models below (see Table 2.2).
Data preprocessing, gene matching and gene ltering: Microarray images were
scanned and summarized by manufacturers' defaults. Data from Aymetrix arrays were
processed by RMA method and data from Illumina are processed by manufacturer's soft-
ware for probe analysis. When samples in each study were processed in multiple batches,
potential batch eects were evaluated and normalizations were performed to correct batch
biases when necessary. Probes (or probe sets) were then matched to ocial gene symbols
using Bioconductore package. When multiple probes (or probe sets) matched to an iden-
tical gene symbol, the probe that generated the best disease association (by paired t-test)
was selected to match to the gene symbol. This selection may cause potential bias but can
increase statistical power in such weak-signal data. After genes were matched across ve
studies, 16,715 unique gene symbols were available across all ve studies and intensities were
all log-transformed (base 2). Two sequential steps of gene ltering were then performed. In
the rst step, we ltered out genes with very low gene expression that were identied with
small average expression values across majority of studies. Specically, mean intensities of
each gene across all samples in each study were calculated and the corresponding ranks were
obtained. The sum of such ranks across ve studies of each gene was calculated and genes
with the highest 30% rank sum were considered un-expressed genes (i.e. small expression in-
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tensities) and were ltered out. Similarly, in the second step, we ltered out non-informative
(small variation) genes by replacing mean intensity in the rst step with standard deviation.
Genes with the lowest 40% rank sum of standard deviations were ltered out. Supplement
Figure 1 shows the preprocessing diagram and the number of genes remained in each pre-
processing step. Finally, 7,020 matched genes (16715 0:7 0:6 = 7020) in ve studies were
analyzed.
2.3 METHODS
2.3.1 Single study analysis for DE gene detection
Paired t-test and Wilcoxon signed rank test:As a comparison, paired t-test andWilcoxon
signed rank test were performed. These two methods took into the MDD and control paired
design into consideration but ignored the confounding covariates.
Random intercept model (RIM) and xed eects model (FEM): To account for
paired design (MDD samples paired with corresponding controls) and existence of MDD re-
lated covariates, we applied a random intercept model (RIM). For a given gene g, we t the
model
Ygik = g + g0X0ik +
LX
l=1
glXlik + k + gik; (2.1)
In the model, Ygik was the gene expression value of gene g( g  G) and sample i (i = 1 for
control and 2 for MDD) in pair k(1  k  K). X0ik was the disease label that took value one
if the sample was MDD and Zero if sample was a control. Xlik represented values for potential
confounding covariate l (1  6; 0-1 binary for alcohol, drug and suicide and numerical for
age, pH and PMI). k was the random intercept from a normal distribution with mean zero
and variance  2g , which represented the deviation of averaged expression values in the kth
pair from the average in the whole population. Finally, gik were independent random noises
that followed a normal distribution with mean zero and variance 2g . Under this model, g0
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was the disease eect of gene g and was the parameter of major interest. To obtain an MDD-
associated biomarker candidate list in a single study analysis, likelihood ratio test (LRT) was
used to assess the p-values of testing H0 : g0 = 0 (vs HA : g0 6= 0). The p-values were
then be corrected by Benjamini-Hochberg procedure [8] for multiple comparison.
Fixed eects model (FEM) below ignores the paired design while still considers the
covariates in the model. It can be used when diseased and control samples are not paired.
Ygik = g + g0X0ik + s
LX
l=1
glXlik + gik (2.2)
RIM and FEM with variable selection: Although RIM model can eectively ad-
just for confounding covariates in DE gene detection, the small sample size (10-25 pairs) and
relatively high number of potential confounders (6 covariates) can make the model inecient
and impractical. In this paper, we developed and evaluated two choices of variable selection
procedures in the random intercept model (namely, RIM BIC and RIM minP). Specically,
all possible RIM models that included at most two (0, 1 or 2) clinical variables were computed
and compared. In RIM BIC, the model with the smallest Bayesian Information Criterion
(BIC) [84] value was selected. For RIM minP, we selected the model that yielded the small-
est p-value associated with the likelihood ratio test for testing the disease eect H0 : g0 = 0.
Conceptually, BIC selected the model with the best model tting and prediction while minP
focused on the model that gave the best statistical signicance of the disease eect. This
additional variable selection avoided to include more than 2 clinical variables in the model
and allowed assessment of biomarkers aected by dierent sets of covariates in each gene
(e.g. gene A is confounded by alcohol while gene B is confounded by drug), which biologi-
cally gave more appealing conclusions and interpretations. Similar to RIM model, likelihood
ratio test were used to generate p-values of testing H0 : g0 = 0 in each gene for the selected
model by BIC or minP. These attached p-value numbers were, however, not the true p-values
for DE gene detection since they were biased from the variable selection procedure and the
type I error control was voided. As a result, we performed a permutation test that randomly
permuted the disease labels within each pair to generate a null distribution for p-value as-
sessment. Figure 2.1 shows the simulated null distribution from permutation analysis. The
skewed distribution deviating from uniform distribution between 0 and 1 showed the need
25
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
minP: The density plot of p−values
 under null
De
nsi
ty
MD1_ACC
MD2_ACC
MD3_ACC
MD1_AMY
MD3_AMY
Uniform
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.5
1.0
1.5
2.0
BIC: The density plot of p−values 
 under null
De
nsi
ty
MD1_ACC
MD2_ACC
MD3_ACC
MD1_AMY
MD3_AMY
Uniform
Figure 2.1: Simulated null distributions of disease eect p-value in the best model (left:
RIM minP; right: RIM BIC) from permutation analysis in the ve MDD studies. The
result shows bias (deviation from uniform distribution) caused by variable selection.
of the permutation analysis for p-value correction. Subsequently, the resulting unbiased p-
values after permutation correction were then corrected by Benjamini-Hochberg procedure
for multiple comparison in each study for DE gene detection. Detailed algorithm of the per-
mutation analysis is described in AppendixA. In contrast to RIM minP and RIM BIC, we
denote by RIM ALL the RIM model that includes all covariates without variable selection.
Testing signicance of interaction terms of each covariate: In the literature, age
as well as other covariates has been found to be confounders of the disease eect with
signicant interaction term in some important biomarkers. [34, 39] In other words, the disease
eect on gene expression may be aected by age dierently in older and in younger cohorts.
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Table 2.3: The number of signicant interaction terms between disease state and covariates in
FEM model and RIM.
FEM RIM
M
D
1
A
C
C
M
D
2
A
C
C
M
D
3
A
C
C
M
D
1
A
M
Y
M
D
3
A
M
Y
M
D
1
A
C
C
M
D
2
A
C
C
M
D
3
A
C
C
M
D
1
A
M
Y
M
D
3
A
M
Y
FDR=0.05
Age 0 0 0 0 0 54 1 0 0 0
pH 0 1 0 0 0 0 7 2 0 0
PMI 0 0 0 0 0 0 2 0 0 0
To evaluate the overall impact of the interaction terms in each covariate, we performed the
following simple linear model
Ygik = g + g0X0ik + glXlik + glX0ikXlik + gik (2.3)
, and random intercept model
Ygik = g + g0X0ik + glXlik + glX0ikXlik + k + gik; (2.4)
where the notations were the same as in FEM model and RIM model with only one covariate
l included and a corresponding interaction term involved. We performed likelihood ratio test
for H0 : gl = 0 to test the statistical signicance of the interaction term of gene g and
covariate l. Table 2.3 summarizes the number of signicant interaction terms in the genome
of each covariate. The result shows that the interaction terms between each covariate (Age,
pH or PMI) and MDD were not signicant in most of the genes under false discovery rate
FDR = 5% (Benjamini-Hochberg correction). As a result, we did not consider the interaction
terms in our RIM models hereafter.
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2.3.2 Meta-analysis for DE gene detection
Among the many microarray meta-analysis methods used in the literature, most methods
have their pros and cons depending on the data structure and biological goal [47, 78]. In this
paper, we compared three most popular methods described in sections 1.4.1.1 ,1.4.1.3,1.4.2.2,
repectively, Fisher, maxP and IVW.
2.3.3 Pathway analysis
We applied Fisher's exact test to detect enriched pathways in detected DE gene lists from
individual study analyses and three meta-analysis methods. Pathways were obtained from
the MSigDB database [91] and Gene Ontology, in which we only considered pathways that
included at least ve genes. We evaluated C1-C4 in MSigDB and gene ontologies in "GOstats"
package in Bioconductor. In the Fisher's exact test, suppose a total number of g genes
in the genome were considered, among them t genes were in the pathway, l genes were
contained in the biomarker list and c genes were common to the target pathway (gene
set) and the biomarker list. The p-value of the pathway enrichment was calculated from a
hypergeometric distribution by p =
Pmin(l;t)
x=c
 
t
x
 
g t
l c

=
 
g
l

. We evaluated p-values for each
pathway independently and then corrected the p-values by Benjamini-Hochberg procedure
for multiple comparison to generate q-values. As will be seen in Figure 6, the three meta-
analysis methods detect dierent sets of DE genes. To avoid bias and as an attempt to retain
advantages from all three meta-analysis methods, we develop a minimum p-value method
(minP) for integrating results from Fisher, maxP and IVW. Specically, a minP statistics is
dened as UminPg = min(p
Fishe
g r; p
maxP
g ; p
IV W
g ), where p
Fisher
g , p
maxP
g and p
IV W
g are p-values
of gene g generated by each meta-analysis method. Under null hypothesis, UminPg follows a
beta distribution with degrees of freedom 1 and 3. The resulting p-values are then adjusted
by Benjamini-Hochberg procedure for q-values.
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2.3.4 Post hoc analysis on the confounding variables after meta-analysis
An essential advantage of our gene-specic variable selection scheme is the possibility of
post hoc analysis on the selected confounders across studies in a genome-wide scale. Three
questions can be explored and answered: (1) Which variable(s) is the most or least frequently
included in the model selection to confound with disease eect? (2) Are variables repeatedly
selected across studies more frequently than by random (e.g. alcohol is selected in most or
all studies in a given gene)? (3) Are the directions of eect sizes of a variable consistent
across studies (e.g. patients who take alcohol have higher expression than non-alcohol in
most studies for a given gene)? For the rst question, we rst generated a list of DE genes
under a given FDR threshold and counted the frequency of each variable being selected in
the gene list. The variables were ranked according to the frequencies in each study and a
rank average of each variable was calculated across ve studies. A small averaged rank of a
given gene showed frequent appearance of the variable in the DE genes' models and was a
frequent confounder. For question (2), we computed a pair-wise co-appearance score (T1)
for a given gene set and assessed its statistical signicance. For example, VGF in Table 4
had detected age eects in 2 studies, alcohol eects in 3 studies, anti-depressant eect in 1
study and suicide eect in 3 studies. By summing up co-appearing pairs of the ve studies in
each variable, we obtained a T1;g statistics of 7 (C
2
2+C
3
2+0+C
3
2 = 7 ) for g=VGF. Summing
up all 10 genes, we obtained T1 =
P
g T1;g = 66. Permutation test was then performed to
assess the statistical signicance of T1.
To answer question (3), we further computed rate of expression concordance among all
co-appearance pairs. Specically, we examined all co-appearing pairs that contributed to
T1 and count the number of pairs that are concordant (up-regulation in both studies or
down-regulation in both studies). The total aggregated score for pair-wise concordance was
denoted as T2 and the ratio of concordance was R = T1=T2. In the example of Table 4, 45
out of 66 co-appearing pairs were concordant and R = 0:68. Similarly, permutation test was
performed to assess the statistical signicance of observed R scores. Detailed mathematical
notation and permutation algorithm are outlined in Appendix B.
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2.3.5 Evaluation and simulation
To evaluate performance of dierent models and methods in a real data analysis, we compared
the number of detected DE genes and the statistical signicance of important pathways.
For the former criterion, we argue that with adequate modelling and multiple comparison
correction, detecting more DE genes shows better statistical power of a method and should
be a preferred method. There is, however, no rigorous proof to reason that detecting more
DE genes guarantees better performance of a method, in terms of its type I error control
and statistical power. Since the type I error and statistical power could not be evaluated
in real data analysis, we performed extensive simulations to facilitate the evaluation. For
a given gene, we considered three variables of a continuous vector of gene expression Y ,
a corresponding binary vector of disease state X and multiple vectors of potential binary
confounding covariate Z. Figure 2.2 shows three correlation structures of interest among
(X; Y; Z) that are systematically simulated. Scenario I demonstrated that both disease
state X and confounding variables Z aect gene expression, a model we are most interested
in this paper. Scenario II and III showed situations when confounding variables Z did
not directly aect gene expression Y . In these latter two scenarios, including confounding
variables Y in the model should not improve performance. The detailed simulation scheme
and evaluation criteria are available in the Supplement Materials Part III. For each scenario,
we simulated a data set with 1000 independent genes and 50 samples (25 diseased and 25
controls). Among the 1000 genes, 100 are true DE genes and 900 are non-DE genes. t-
test, FEM minP, FEM BIC and FEM ALL were applied to evaluate the eect of modelling
confounding variables and variable selection in each correlation structure. We repeated the
simulation 50 times. Type I error and power were calculated for each method in each data
set and averaged over 50 repeated simulations.
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(I) Z
Y X
(II) Z
Y X
(III) Z
Y X
Figure 2.2: Three correlation structures of interest among disease variables X, gene expression
variable Y and covariates Z that are used in the simulation. Scenario I: gene expression
depends on both disease state and covariates. Scenario II: gene expression depends only on
disease state. Scenario III: gene expression depends on disease state directly and depends
on covariates indirectly through disease state.
2.4 RESULTS AND DISCUSSION
2.4.1 Recommended statistical framework
From the motivating MDD example, we proposed a statistical framework to consider poten-
tial confounding covariates, paired design and gene-specic variable selection in the meta-
analysis modelling. Figure 2.3 shows a diagram of the framework. The framework consisted
of four major steps: individual study analysis, meta-analysis, pathway analysis and post
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hoc analysis. In the rst "individual study analysis" step, collinearity of confounders was
assessed and RIM minP or FEM minP method with variable selection was applied depend-
ing on paired or un-paired design. One or multiple meta-analysis methods were applied and
compared in Step II. Pathway analysis was then performed on the detected DE gene list(s)
to identify enriched pathways in Step III. Finally, post hoc analysis was performed to sum-
marize importance of each confounding variables and to evaluate the consistency of disease
eects and confounders' eects across studies. This framework is general and abstract that
can be applied to any weak-signal data from a complex disease similar to the motivating
MDD example.
2.4.2 Comparison of various methods in single study analysis
Adjusting confounders and variable selection improve DE gene detection For each
single study analysis, we compared the number of detected DE genes under dierent p-value
thresholds (p=0.001, 0.005, 0.01 and 0.05) from dierent methods. In Figure ??, RIM minP
and RIM BIC both detected more DE genes than RIM ALL, showing the fact that variable
selection helped to ignore irrelevant clinical variables when sample size was small. Among
the two variable selection methods, RIM minP detected more genes than RIM BIC, support-
ing that the focus of RIM minP to obtain the most signicant disease eect outperformed
RIM BIC's focus for best model tting in this example. Under p=0.005, RIM minP de-
tected (1.7 to 2.3) times of DE genes than RIM BIC and (1.5 to 6) times than RIM ALL in
the ve studies. The result suggested that RIM minP is the most eective method in this
data set to incorporate confounding variables in the model. In Figure 2.5, RIM minP was
further compared to paired t-test (PT) and Wilcoxon signed rank test (WT) and was found
to detect more DE genes, showing the advantage of incorporating confounding covariates in
the model. RIM minP identied (0.8 to 3.9) times of DE genes than PT and (2.5 to 6.4)
times than WT under p=0.005.
Paired design improves DE gene detection: To evaluate the improvement of in-
cluding paired design in the model, we compared RIM minP and FEM minP in Figure
2.6. We observed more powerful DE gene detection of RIM minP compared to FEM minP.
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Figure 2.3: Three correlation structures of interest among disease variables X, gene expression
variable Y and covariates Z that are used in the simulation. Scenario I: gene expression
depends on both disease state and covariates. Scenario II: gene expression depends only on
disease state. Scenario III: gene expression depends on disease state directly and depends
on covariates indirectly through disease state.
RIM minP detected more DE genes than FEM minP in most studies except for MD1 AMY.
The result showed that pairing cases to controls by age, race and sex usually helped increase
statistical power.
Conclusion In conclusion, incorporation of potential confounding covariates with variable
selection and considering paired design in the model performed the best. We used RIM minP
hereafter for single study analyses and as the foundation of meta-analysis. In Table 1, the
rst ve columns show the number of biomarkers detected by RIM minP under dierent
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Figure 2.4: Comparison of RIM minP, RIM BIC and RIM ALL in individual study analyses.
The result showed that RIM minP detected the largest number of DE genes among the three
methods.
p-value and false discovery rate (FDR) thresholds. After multiple comparison correction
by Benjamini-Hochberg procedure, only MD3 ACC detected one DE gene and all other four
studies detected none DE gene under FDR=5%. This motivated us to perform meta-analysis
below to increase the statistical power of DE gene detection.
2.4.3 Comparing three meta-analysis methods in combining all ve studies
In the literature, many microarray meta-analysis methods have been proposed and compared
[13, 47, 78]. As was discussed in the method section, dierent methods have dierent strength
for detecting dierent types of dierentially expressed genes. In Li et al [52], genes that are
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Figure 2.5: Comparison of RIM minP, paired t-test (PT) and Wilcoxon signed-rank test
(WT) in individual study analyses. The result showed that RIM minP detected the largest
number of DE genes among the three methods.
dierentially expressed in all studies were termed as HSA type (hypothesis setting A) while
genes dierentially expressed in at least one study was called HSB type. Among the three
methods compared in this paper, maxP and IVW were methods that detect HSA type DE
genes, while Fisher's method detected HSB type DE genes. Table 2.4 shows the number
of detected DE genes from ve individual study analyses and from meta-analysis of ve
studies (Meta 3ACC+2AMY by Fisher, maxP and IVW) under dierent p-value and FDR
threshold. A Venn diagram of DE gene lists detected by three meta-analysis methods under
p=0.005 is shown in Figure F1. The result showed that the three meta-analysis methods
detected dierent sets of DE genes, suggesting dierent algorithms and assumptions behind
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Figure 2.6: Comparison of RIM minP and FEM minP in individual study analyses. The
result showed that RIM minP usually detected more DE genes.
the methods. Figure 2.8 shows heamaps on genes detected by Fisher alone (A), maxP alone
(B) or both (C). In Figure 2.8 A, majority of DE genes detected by Fisher but not by maxP
were dominated by strong dierential expression in one or two studies (many in MD3 AMY
and some in MD2 ACC or MD3 ACC). Although Fisher's method has been popularly applied
in the microarray meta-analysis literature, the result showed its weakness to be dominated by
single strong signal studies that included potential false positives. On the other hand, maxP
had better power to detect many genes with weak DE evidence in all studies (Figure 2.8B)
that Fisher's method cannot detect. Conceptually, we were more interested in identifying
genes dierentially expressed across all studies through maxP or IVW although we still
apply a unied minimum p-value method to integrate advantages of all three meta-analysis
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Table 2.4: Results of individual study analyses and meta-analysis combining p-values calculated
from RIM minP
Individual studies Meta-analysis
(3ACC) (3ACC+2AMY) (2AMY)
MD1 ACC MD2 ACC MD3 ACC MD1 AMY MD3 AMY Fisher maxP IVW Fisher maxP IVW Fisher maxP IVW
p=0.001 5 25 29 3 118 73 123 246 220 255 425 64 50 340
p=0.005 42 122 123 30 448 304 371 572 658 664 569 283 185 828
FDR=0.05 0 0 0 0 0 8 86 106 574 605 552 0 0 143
FDR=0.1 0 0 1 0 882 149 534 812 1815 1909 616 33 0 996
methods. For a complete comparison, we also performed partial meta-analysis by combining
three ACC studies (Meta 3ACC) and two AMY studies (Meta 2AMY). The results are
outlined in Table 2.4.
To further evaluate the biological meaning of the detected DE genes by various methods,
pathway analysis was performed. For a fair comparison, DE gene lists detected by vari-
ous methods (individual study analyses or Fisher, maxP and IVW meta-analysis methods)
under p=0.005 without multiple comparison adjustment were evaluated and Table 2 (See
Appendix) shows the pathway analysis results. Comparing single study analysis and meta-
analysis results in pathway analysis, the p-values of many important psychiatric related path-
ways were much smaller in the meta-analysis results than those from single study analysis,
showing increased statistical power by meta-analysis in the functional analysis. For example,
the gene set "ASTON MAJOR DEPRESSIVE DISORDER DN" obtained from a previous
MDD study had none to marginal statistical signicance in pathway analysis of each individ-
ual study. Meta-analysis by Fisher or maxP method generated high statistical signicance
from pathway analysis (p=4E-12 and 2E-9). Pathways with known or putative correlation
with MDD were marked with asterisk in Table (in Appendix). Many of these insightful
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Figure 2.7: Venn diagram of DE gene lists obtained from Fisher, maxP and IVW under
0.005 p-value threshold.
pathways were, however, generated by split of the three methods, suggesting that Fisher,
maxP and IVW may have their own characteristics and advantages to detect dierent path-
ways. To generate a more unbiased and unied result, we applied a minimum p-value (minP)
method to integrate pathway analysis results from Fisher, maxP and IVW (details described
in "Method" section). Table includes 87 pathways (in C2, C3 and gene ontology databases)
detected by minP under a loose p-value threshold at 0.01 without multiple comparison. C1
and C4 databases in MsigDB did not generate any pathway with high statistical signicance
(3 out of 326 pathways in C1 and 9 out of 881 in C4 with p-value smaller than 0.01) and thus
are excluded from the presentation. Many pathways listed in Appendix Table 1 were found
related to signal transduction, neural development and neuropsychiatry, providing deep in-
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Figure 2.8: Heatmap of minus log10-transformed p-values obtained from all ve studies and
meta-analysis for detecting DE genes. Red indicates small p-values and green indicates large
p-values. (A) DE genes detected by Fisher's method but not by maxP method; (B) DE
genes detected by maxP but not by Fisher's method; (C) DE genes detected by both Fisher
and maxP method.
sight to the underlying genetic mechanism of MDD. In C2 curated gene set category, the
gene sets ("ASTON MAJOR DEPRESSIVE DISORDER DN") includes numerous down-
regulated genes that are specic to oligodendrocytes [3], the major myelin-forming cell type
in the brain, which have been shown to be reduced in numbers in depression [41]. The gene
set ("BLALOCK ALZHEIMERS DISEASE DN") highlights the potential biological interac-
tion between the co-occurrence of de-pressive symptoms in Alzheimer disease patients. Other
identied gene sets relate to biological functions that have been identied as causative, or at
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least as risk factors for the development of depres-sion (i.e. interleukin-related function, "MA-
HAJAN RESPONSE TO IL1A UP", "MARZEC IL2 SIGNALING UP"). Other gene sets
potentially relate to biological functions involved in the therapeutic treatment of the illness
(ie, "ROPERO HDAC2 TARGETS ", "RODRIGUES THYROID CARCINOMA DN". In
C3 motif gene sets, six motifs "CCTGCTG,MIR-214", "CTTTGCA,MIR-527", "CAGGTG
V$E12 Q6", "GAANYNYGACNY UNKNOWN", "V$SP1 Q2 01", "AAGCCAT,MIR-135A,
MIR-135B", "V$CDPCR3HD 01" for various miRNA and transcription factor targets had
p-values smaller than 0.001. For gene ontologies, many pathways related to metabolism and
signal transduction were identied. In particular, "cell communication", "nervous system de-
velopment", "synaptic transmission"and "ensheathment of neurons"were insightful pathways
related to MDD.
2.4.4 Distribution of covariate inclusion in the models of detected DE genes
To evaluate the impact of covariates on the gene expression values and degree of confounding
with disease eect, especially among DE genes, we counted the number of appearances of
covariates in the RIM minP models for 664 DE genes detected by maxP method under 0.005
p-value threshold. We calculated the rank of each covariate in each study and computed rank
averages of each co-variate to indicate relative degree of frequency that a covariate impacted
gene expression and confounds with disease eect (see Table 2.5). PMI (appeared in 16-24%
models of 664 DE genes) and pH (appeared 14-37%) consistently had high rank, indicating
that they seldom confounded and inuenced the disease eect estimate. Age (appeared 28-
39%), alcohol (appeared 25-43%) and antide-pressant (appeared 17-48%) were three factors
that consistently ranked among the most inuential factors. Suicide ranked among the lowest
in three studies (appeared 44-52%) but the highest in two studies (appeared 15-19%). The
ranking of MD3 ACC and MD3 AMY was highly correlated (Spearman correlation=0.9)
and the correlation between rankings of MD1 ACC and MD1 AMY was also high (Spearman
correlation=0.71). The high within cohort correlations showed a cohort dependent structure
and suggested that more studies may be needed to provide empirical evidence on the covariate
impacts, particularly for the impact of antidepressant and suicide.
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Table 2.5: Frequency of covariates appearing in RIM minP models among 664 DE genes detected
by maxP method under p-value threshold 0.005. Rank is shown in parentheses and rank average of
each covariate is calculated to indicate relative degree of frequency that a covariate impacts gene
expressions and confounds with disease eect
MD1 ACC MD2 ACC MD3 ACC MD1 AMY MD3 AMY rank average
Age 186 (4) 258 (2) 238 (2) 192 (3) 233 (3) 2.8
Alcohol 243 (3) 230 (3) 165 (4) 286 (1) 173 (4) 3
Antidep 291 (1) 115 (6) 202 (3) 277 (2) 320 (1.5) 2.7
pH 247 (2) 143 (4) 127 (6) 176 (4) 94 (6) 4.4
PMI 109 (5) 139 (5) 160 (5) 154 (5) 109 (5) 5
Suicide 97 (6) 295 (1) 345 (1) 126 (6) 320 (1.5) 3.1
To further explore eects of covariates, we identied a set of 10 genes that have been
previously associated with MDD in the literature (see Appendix Figure F). Intuitively, we
expected that a co-variate should be included in the model across studies more frequently
than by random and eects of a covariate should have consistent dierential expression direc-
tion across studies. We constructed two hypothesis testing using the co-appearing statistics
T1 and concordant ratio statistics R described in Method section and performed the tests on
the 10 MDD-related genes and on 664 DE genes detected by maxP under p=0.005 threshold.
The result showed weak to marginal statistical signicance of the rst hypothesis (p=0.172
for the 10 MDD genes and p=0.05 for 664 DE genes), suggesting covariates were consistently
selected across studies. For the second hypothesis, tests for both 10 MDD gene list and
664 DE gene list were statistically signicant (p=0.019 and 0.002). The result demonstrated
that covariates overall impacted gene expression changes consistently and confounded with
disease eects among the two MDD-related candidate gene lists tested.
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2.4.5 Simulation results
Simulation results are shown in Table 2.6. In Scenario I simulation, the eect of disease
state X on gene expression Y was confounded by two out of ten clinical variables in Z. The
result showed that t-test had low statistical power due to the confounders (power=0.679).
FEM ALL also had low power due to the inclusion of all ten clinical variables in the model
(power=0.697). Both FEM models with variable selection perform well. FEM BIC per-
formed slightly better than FEM minP (power=0.729 versus 0.746). The type I errors for all
methods were close to the nominal 5% rate, showing adequacy of the models and statistical
inference. For Scenario II, all clinical variables were independent from the gene expression.
Not surprisingly, t-test performed the best with statistical power 0.938. FEM minP and
FEM BIC both had similar high power at 0.929 and 0.925. FEM ALL forced all variables
in the model and obtained a statistical power at 0.85. From Scenario I and Scenario II sim-
ulation, FEM BIC and FEM minP performed well in both extreme cases, demonstrating its
sensitivity and robustness. Scenario III examined a situation that variables Z impact gene
expression Y through disease state X. Similar to Scenario II, t-test performed the best in this
situation since Z is not confounded (power=0.938). Both FEM BIC and FEM minP had sim-
ilar high power (power=0.925 and 0.916) but FEM ALL again had low power (power=0.851).
Overall, the simulation results conrmed our ndings in MDD data analysis that variable
selection by BIC and minP procedures had better sensitivity and robustness in DE gene
detection.
2.5 DISCUSSION
In this paper, we described a statistical framework, namely MetaACV (Meta-analysis ad-
justed for confounding variables), to tackle weak signal expression proles that have small
sample size, case-control paired design and confounding covariates in each study. The re-
sults showed increased statistical power from confounding variable adjustment, paired design
modelling and meta-analysis in this genomic setting and more profound biological ndings
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Table 2.6: Evaluation of t-test, FEM minP, FEM BIC and FEM ALL methods by simulations.The
Average of Type I errors, average of statistical powers, and average number of detected DE genes
by each method are shown.
Type (I) error Power (%) DE gene number
(s.e) (s.e) (s.e)
Scenario t-
te
st
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L
I
estimate 0.051 0.048 0.050 0.052 80.4 87.2 87.9 84.0 37.3 49.4 52.8 43.5
s.e (0.001) (0.001) (0.001) (0.001) (0.005) (0.004) (0.004) (0.005) (1.228) (1.063) (1.029) (1.162)
II
estimate 0.051 0.052 0.050 0.051 93.8 92.9 92.5 85.0 73.4 73.0 69.8 49.7
s.e (0.001) (0.001) (0.001) (0.001) (0.003) (0.003) (0.003) (0.005) (0.846) (0.915) (0.956) (1.368)
III
estimate 0.051 0.053 0.051 0.051 93.8 92.5 91.6 85.1 71.8 68.3 66.5 45.8
s.e (0.001) (0.001) (0.001) (0.001) (0.003) (0.004) (0.004) (0.005) (0.928) (0.940) (0.876) (1.047)
have been discovered in MDD neurobiology. Pathway analysis and post hoc analysis of vari-
able selection revealed insightful biological conclusions. Simulations under three correlation
structures were performed to verify improved performance of our proposed frame-work. In
the literature, most psychiatric disease-related microarray studies of similar design either
ignored the clinical variables or applied simple linear regression to include all variables in
the model. Our results clearly show limits to those two approaches. To our knowledge, this
is the rst paper, which systematically considers the critical elements in the data structure
in order to obtain more accurate DE gene and pathway detection. The framework is general
and can be applied to microarray meta-analysis of other complex diseases with similar data
structure. Specically, this approach will be of great use in human post-mortem studies of
the brain, where confounding factors are intrinsic (1) to the nature of the cohorts (demo-
graphic parameters), (2) to their method of collection (post-mortem interval) and (3) to the
illness per se (clinical heterogeneity). Since dilution of expression signal is likely to occur in
complex tissue such as the brain, DE genes often show small and weak eects, so reducing
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the statistical interference of confounding factors is critical to detect disease eects. In the
variable selection of the RIM model, we tested both BIC and minP approaches. The real
data analysis showed that minP seemed to identify more DE genes and pathways in the
MDD example while simulations showed similar performance and statistical power of the
two methods. Another potential alternative is to apply popular regularization and shrinkage
methods, such as Lasso or ridge regression, in the variable selection. A prohibitive down-side
of such approaches is its extensive computation load for ge-nome-wide analysis, particularly
in the estimation of the tuning parameter lambda. In our analysis, BIC and minP procedures
limited to up to two covariates in the model balance well in biological inter-pretation and
computation feasibility.
The goal of this study was to determine optimal analytical ap-proaches for complex
datasets with multiple putative confounding variables. For this purpose, we focused on
datasets produced by our group, in order to avoid additional confounding factors due to
dierences in laboratory protocols, brain bank collection, tissue treatment and sample han-
dling. Now that we have established such analytical guidelines, the next step will be to
increase the scope of meta-analyses by including additional datasets that are progressively
made available in the literature. However, as expected, this also comes with added variabil-
ity, which necessitates the development of complementary mathematical tools. For instance,
we have designed a data-driven "meta-QC" quality control approach to rigorously assess the
quality and potential load of confounding variables for any microarray datasets (Kang et al,
paper in preparation). This preliminary quality control test is critical to assess whether the
inclusion of additional datasets will increase the analytical power, or be detrimental to the
meta-analysis, due to substantial quality control confounding load. Finally, as briey eluci-
dated in this report, mechanisms underlying neurological and neuropsychiatric disorders are
likely to involve a distributed sets of brain regions linked in functional neural networks. The
detection of molecular pathologies associated with those disorders will thus also critically
depend on a priori hypotheses for converging or opposing eects in selected brain regions,
for the presence (or not) of control brain regions. For instance, genetic risk factors may be
hypothesized to similarly aect biological pathways across brain regions, while compensatory
mechanisms leading to pathological dysfunction may display regional specicity, depending
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on the respective activation or inhibition of dierent components of neural networks. Hence,
the biological impact of the studies performed here will be investigated, validated and dis-
cussed more in-depth elsewhere. The studies combined in this paper have signicant cohort
features that may introduce signicant heterogeneity. The ve studies came from three dis-
tinct cohorts (MD1, MD2 and MD3), dierent sexes (male and female), array platforms
(Aymetrix and Illumina) and brain regions (ACC and AMY). Future research is needed
to further decipher such study-specic features. In this paper, we performed separated
meta-analysis by brain region (Meta 3ACC and Meta 2AMY) for an initial comparison. A
future direction is to collect more studies and apply meta-regression techniques to identify
sex-specic or brain-region-specic genes in a unied meta-analysis.
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3.0 META-REGRESSION MODELS TO DETECT BIOMARKERS
CONFOUNDED BY STUDY-LEVEL COVARIATES IN MAJOR
DEPRESSIVE DISORDER MICROARRAY DATA
3.1 INTRODUCTION
Meta-regression has grown in popularity in recent years, paralleling the increasing numbers
of systematic and meta-analysis published medical literature. Traditional methods of meta-
analysis attempt to combine results in order to obtain a single summarized eect size, such as
the overall weighted eect size estimated by random eects model[44, 15]. The observed eect
size in each study is an estimated , with some imprecision , of the true eect in that study.
Usually, the statistical heterogeneity refers to the variation of eect sizes across studies, which
cold result from clinical or methodological dierences among the studies or could simply be
because of chance[93]. In general, failure to consider the heterogeneity can cause bias in the
results of a meta-analysis. Therefore, the potential scientic value of explorations of sources
of heterogeneity has been emphasized in the past [9, 93, 94, 95],perhaps,this is the reason
that meta-regression is now becoming a more widely used technique.
We conducted a systematic search from PubMed, SciSearch, Social SciSearch and AMEC
(Allied and Complementary Medicine) using the search terms "meta-regression" in order to
identify publications on meta-regression. The systematic review produced 205 publications
relevant to meta-regression. We categorized the publications into two categories based on the
primary focus of the article: The rst category was the main meta-regression methods: xed
eects models (1 Publications [38] ), random eects models (5 Publications [10, 11, 60, 45, 49])
and Bayesian or hierarchical models (2 publications[35, 89]); the second category was the
application papers using the methods mentioned in the rst category(197 publications). In
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addition, there were two review paper about meta-regression [94, 5]. Among these papers
related to meta-regression, we found that the the meta-regression was mainly used in clinical
studies, and has never been used in genomic studies due to the availability of microarray
studies. For example, it has been used to relate the standardised treatment response in RCTs
to study-level variables (study duration, number of follow-up assessments, outpatients versus
inpatients, per protocol analysis versus intention to treat analysis)[71], vaccine ecacy to geo-
graphical latitude[19], coronary risk benet to serum cholesterol reduction [62]and properties
of diagnostic tests to methodological quality of diagnostic accuracy studies[63]. In this paper,
we will explore the use of meta-regression in gene expression analysis using 8 major depres-
sive disorder (MDD) studies in which each study has three study-specic factors(sex,brain
region and array platform). MDD is a heterogeneous illness with mostly uncharacterized
pathology. Despite many gene expression studies of MDD [3, 53, 85, 88, 87], the biological
mechanisms of MDD remain mostly uncharacterized [7]. MDD is thought to be a complex
and heterogeneous disease [72], associated with multiple genetic, genomic, post-translational,
and environmental factors. Furthermore, patients might have varying disease severity, with
some having psychotic features as well as exposure to a variety of medications and dosage
levels to control their illness. Secondly, the genetic disease eects are potentially confounded
by many covariates, which include (1) demographical variables such as age, gender and race;
(2) clinical variables such as anti-depressant drug usage, suicide and alcohol consumption;
(3) technical variables inherent in the use of post-mortem brain samples, such as the pH
level of brain tissues, brain region and postmortem interval (PMI). If the statistical models
employed to identify dierentially expressed genes fail to incorporate these sources of hetero-
geneity, not only can this reduce the statistical power, but also it will introduce sources of
spurious signals to the gene detection. In our previous paper [100], we proposed a statistical
framework to tackle weak signal expression proles that have small sample size,case-control
paired design and confounded with these sample-level covariates in each study. The results
showed increased statistical power by incorporating the following considerations in the anal-
ysis: (1) inclusion of confounding clinical variables, (2) gene-specic variable selection, (3)
random eects for paired design, and (4) meta-analysis. More MDD related biomarkers and
pathways were detected that greatly enhanced understanding of MDD neurobiology.
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The studies combined in that paper have signicant cohort features that may introduce
signicant heterogeneity. The ve studies came from three distinct cohorts (MD1, MD2
and MD3), dierent sexes (male and female), array platforms (Aymetrix and Illumina)
and brain regions (ACC and AMY). In previous paper, we only had ve studies, so we just
performed sub-group meta-analysis by brain region (Meta3 ACC and Meta2 AMY) for ini-
tial comparison and did not decipher this study-specic features. After collecting another
three MDD studies,in this paper, which has an appealing property to identify confounded
study-level covariates and obtain a more accurate disease eect size after adjustment. An im-
proved MetaRG with variable selection (namely MetaRG BIC to be introduced later) will be
performed to accommodate the small number of studies and relatively large number of study-
level variables, especially, some variables may be multi-class variables. The result shows ad-
ditional statistical power to detect gender-dependent and brain-region-dependent biomarkers
that traditional meta-analysis methods, such as random eects model and Fisher's method,
cannot detect.
3.2 METHODS
3.2.1 Description of motivating MDD data
Description of motivating MDD data This research is motivated from the meta-analysis of
combining eight MDD transcriptomic studies. Brain tissues of four patient cohorts (MD1,
MD2 M, MD2 F, and MD3) obtained from dierent sources at dierent time were analyzed.
For all three patient cohorts, tissues from the anterior cingulated cortex (ACC) brain region
were analyzed by microarray experiments independently to generate four microarray studies:
MD1 ACC, C MD2 ACC F, C MD2 ACC M and MD3 ACC. Tissues from the amygdala
(AMY) brain region in MD1 and MD3 cohorts were analyzed to generate MD1 AMY and
MD3 AMY. Similarly, tissues from the dorsolateral prefrontal cortex (DLPFC) brain region
in MD2 cohorts were analyzed to generate C MD2 DLPFC F, C MD2 DLPFC M. Details of
the ve patient cohorts and microarray studies are available in Table 1.1. Within each patient
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cohort, MDD patients were matched to control patients by three demographic variables: age,
sex and race. Three additional clinical variables (alcohol consumption, history of taking anti-
depressant drugs and history of committing suicide) and two technical variables (pH level of
brain tissues and post-mortem interval PMI) are also available for each patient. Six variables
(age, alcohol-consumption, anti-depressant drug, suicide, pH and PMI) are considered as
sample-level covariates. A random intercept model with Bayesian Information Criteria (BIC)
variable selection has been proposed previously to account for these sample-level factors in
single study analysis. For each of the eight microarray studies, three study-level factors
(sex, brain region and array platform) are available and will be considered in the proposed
meta-regression approach in this paper.
3.2.2 Data preprocessing, gene matching and gene ltering
Microarray images are scanned and summarized by manufacturers' defaults. Data from
Aymetrix arrays are processed by RMA method and data from Illumina are processed by
manufacturer's software for probe analysis. When samples in each study are processed in
multiple batches, potential batch eects are evaluated and normalizations are performed to
correct batch biases when necessary. Probes (or probe sets) are then matched to ocial gene
symbols using Bioconductore package. After genes are matched across nine studies, 11840
unique gene symbols are available across all ve studies. Two sequential steps of gene ltering
are then performed. In the rst step, we lter out genes with very low gene expression that are
identied with small average expression values across majority of studies. Specically, mean
intensities of each gene across all samples in each study are calculated and the corresponding
ranks are obtained. The sum of such ranks across nine studies of each gene is calculated
and genes with the lowest 20% rank sum are considered un-expressed genes and are ltered
out. Similarly, in the second step, we lter out non-informative (small variation) genes by
replacing mean intensity in the rst step with standard deviation. Genes with the lowest 20%
rank sum of standard deviations are ltered out. Finally, 7; 577 = 11840(1 0:2)(1 0:2)
matched genes in nine studies are analyzed.
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3.2.3 Single study analysis incorporation sample-level variables
To account for paired design (MDD samples paired with corresponding controls) and sample-
level covariates, we applied a random intercept model (RIM). For a given gene g, we t the
model
Ygik = g + g0X0ik +
LX
l=1
glXlik + k + gik; (3.1)
where Ygik was the gene expression value of gene g(1  g  G) and sample i (i=1,2 represent-
ing control and MDD, respectively) in pair k(1  k  K). X0ik was the MDD indicator that
took value one if the sample was MDD and zero if the sample was a control. Xlik represented
values for clinical variable l (e.g. 0-1 binary for alcohol consumption or numerical for pH
values in brain) and k was the random intercept from a normal distribution with mean zero
and variance  2g , which represented the deviation of averaged expression values in the k
th pair
from the average in the whole population. Finally, gik were independent random noises that
followed a normal distribution with mean zero and variance 2g . Under this model, g0 was
the disease eect of gene g and was the parameter of major interest. To obtain an MDD-
associated biomarker candidate list in a single study analysis, likelihood ratio test (LRT)
was used to assess the p-values of testing H0 : g0 = 0(vsHA : g0 6= 0). Although RIM
model can eectively adjust for confounding varables, the small sample size (9-22 pairs) and
relatively high number of potential confounders (6 covariates) can make the model inecient
and impractical. In previous paper, we performed further variable selection to generate an
optimal random intercept model( RIM BIC), where the "optimal" referred to the model with
the smallest Bayesian Information Criterion (BIC)[84]. Specically, all possible RIM models
that included at most two (0, 1 or 2) clinical variables were computed and compared. The
model with the smallest BIC value was selected. This additional variable selection avoided
to include more than 2 clinical variables in the model and allowed assessment of biomarkers
aected by dierent sets of covariates in each gene (e.g. gene A is confounded by alcohol
while gene B is confounded by drug), which biologically gave more appealing conclusions and
interpretations. Similar to RIM model, likelihood ratio test were used to generate p-values
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of testing H0 : g0 = 0 in each gene for the selected model. These attached p-value num-
bers were, however, not the true p-values for DE gene detection since they were biased from
the variable selection procedure and the type I error control was voided. As a result, we
performed a permutation test that randomly permuted the disease labels within each pair
to generate a null distribution for p-value assessment. Subsequently, the resulting unbiased
p-values after permutation correction were then corrected by Benjamini-Hochberg procedure
for multiple comparisons in each study for DE gene detection. Based on the optimal model
selected, the standardized eect size for each gene was dened as the coecient of MDD di-
vided by its standard error (i.e. ^g0=sg0 in the RIM BIC model) from single study analysis;
sg0 represented the estimated standard error of ^g0.
3.2.4 Meta-analysis and Meta-regression
Fixed eects model: Fixed eects models is one of often used methods of combining eect
sizes when the studies to be combined are homogeneous, in which only within-study vari-
ability is considered. The assumption is that studies use identical methods, samples, and
measurements; that they should produce identical results; and that dierences are only due
to within-study variation. The general model is given by
Ygk = g + gk (3.2)
Under the xed-eect model we assume that there is one true eect size which underlies all
the studies in the analysis, and that all dierences in observed eects are due to sampling
error. Thus Ygk  N(g; 2gk). The most ecient and unbiased estimator of 1 is the weighted
average of estimates where the weights is determined by inverse of their standard errors. The
estimate is
^g =
PK
k=1wgkYgkPK
k=1wgk
; (3.3)
where wgk = S
 2
gk and S
2
gk s the estimated within-study variance in study k for gene g. The
variance of ^g is then
V ar(^g) =
1PK
k=1wgk
: (3.4)
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So, a Z-score to test the null hypothesis that the common true eect g is zero can be
computed using
ZFEMg =
^gp
V ar(^g)
: (3.5)
which follows a standard normal distribution.
Random eect model (REM) is a popular method for combining of eect sizes in meta-
analysis. Choi et al [15] was probably among the rst to raise the issue of meta-analysis
in the context of microarray data to nd DE genes using this method, where the eect size
is dened as the standardized mean dierence d = YD YC
Sp
, where YD and YC represent the
means of disease (MDD) and control groups, respectively and Sp indicates an estimation of
the pooled variation. The corresponding model used was described as:
Ygk = g + gk + gk (3.6)
, where Ygk is the observed eect size in study k for gene g; the parameters gk and
gk are the between-study and within-study errors, respectively. It assume that gk 
N(0;  2g ) and gk  N(0; 2gk), and  2gk and 2gk are the between-study and within-study vari-
ance. Usually, the estimate of 2gk can be produced in each study k. The between-study
variance can be estimated using a method of weighted moments (MM) estimator of  2gk,
which can be derived from the heterogeneity statistic Qg =
PK
k=1wgk(Ygk   ^g)2, where
 = (
PK
k=1wgkYgk)=
PK
k=1wgk is the feasible weighted least-squares estimator with weights
wgk = 1=S
2
gk. Then, the weighted unbiased MM of 
2
g suggested by DerSimonian and Larird
(DL) [22]:  2g = maxf0; (Qg (K 1))=(S1 (S2=S1))g, where wgk = S 2gk , and Sr = wrgk, and
K is the number of studies.The average weighted eect size was estimated as (g) =
P
vgkYgkP
vgk
and V ar((g) = 1=vgk, where vgk = 1=(^
2
g + S
2
gk) . Under the assumption that the gene
expression levels are normally distributed, a z-score to test for DE genes is constructed as,
Zg =
(g)p
V ar((g)
, which follows a normal distribution with zero mean and unit variance.
Random eects meta-regression model with one study-level Knapp and Hartung [60] pro-
posed the following random eects meta-regression model with s single covariate:
Ygk  N(g + gxk;  2g + 2gk); k = 1; 2;    ; K (3.7)
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Where the parameter 2gk stands for the within-study variance, and 
2
g is the between-study
variance. Like in REM, every study k produces an estimate of 2gk denoted S
2
gk. The between-
study variance can be estimated using a method of weighted moments (MM) estimator of
 2g , which can be derived from the heterogeneity statistic ~Qg =
PK
k=1wgk(Ygk   ^g   ^gxk)2,
where ^g and ^g are the feasible weighted least-squares estimator weights wgk = 1=S
2
gk. Then,
the weighted unbiased MM of  2g is given in its truncated form as: 
2
g = maxf0;
~Qg (K 2)
F (wgk;x)
g
with F (wgk; x) =
P
wgk  
P
w2gk
P
wgkx
2
k 2
P
w2gkxk+
P
wgk
P
w2gkx
2
kP
wgk
P
wgkx
2
k (
P
wgkxk)2
When there is no covariate,
the above estimator reduces to the DL estimator.
Random eects Meta-regression model with multiple study-level covariates: Model3.7 can
be straightforwardly extended to the case where there are multiple study-specic covariates.
The general random eect meta-regression model is
Ygk = g +
LX
l=1
glXkl + gk + gk; k = 1; 2;    ; K (3.8)
, which can be written as a matrix form Yg  N(Xg;  2g IK+), where Yg = (Yg1; Yg2;    ; YgK)0
is a K  1 vector including the observed eect sizes from K studies; X = (X0; X1;    ; XL)
is the K  (L + 1)-dimensional predictor matrix with rank r(X) = r < K   1 and X0 =
(1; 1;    ; 1)0 and Xl = (X1l; X2l;    ; XKl)0 l = 1; 2;    ; L; g = (g; g1; g2;    ; gL)0 is
the unknown parameter vector of the xed eects;  2g stands for the between-study variance;
IK is a K  K dimensional identity matrix;  is a K  K dimensional diagonal diagonal
matrix with entries 2gk; k = 1; 2;    ; K, that is,  contains the within-study variances. In
this setting, the method of moment estimator of  2gk is given by[60]: ^
2
g =
Q (K r)
F (X; 1) , where
Q = Y
0
P
0
 1PYg with P = (IK   X(X 0 1X) 1X 0 1),and F (X; 1) = tr( 1  
tr((X
0
 1X) 1X
0
 2X), in which tr(X) denotes the trace of matrix X.
Meta-regression with variable selection : Exploring sources of heterogeneity my result in
false positive conclusions through 'data dredging'[95]. Unlike meta-analysis in clinical or epi-
demiological research where up to hundreds of studies may be available for meta-regression
model, only a small number (e.g. 5-15) of studies are available in a common microarray
meta-analysis. When the number of study-level variables that potentially contribute to het-
erogeneity becomes large (greater than 2-3 studies), the regression model is not applicable.
It is, however, reasonable to assume that only very small number (e.g. 0-1) of variables
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contribute to the expression heterogeneity in each gene and the contributing variables are
gene-specic. This leads to the variable selection approach we adopt in this paper. Specif-
ically, all possible meta-regression models that include at most one (0 or1) study-specic
variables are computed and compared.
MetaRG(wg) : Ygk = g +
LX
l=1
wlglXlk + gk + gk; (3.9)
where wl is the weight assigned to the lth study-level variable and wg = (wg1; wg2;    ; wgL),
which belongs toW = f(w1; w2;    ; wL)jwl 2 0; 1and
P
wl  1g. We denote by BIC(wg) as
the Bayesian Information Criterion value associated with meta-regression modelMetaRG(wg).
The adaptive weight wg is dened as: w

g = (w

g1; w

g2;    ; wgL) = argmin(w2W )BIC(w),
which serves as a convenient basis for gene categorization in follow-up biological interpreta-
tions and explorations. Based on the selected model MetaRG(wg), likelihood ratio test is
applied to test H0 : g = 0 and fgl = 0 if wgl = 1g versus HA : g 6= 0 or fgl 6=
0 if wgl = 1g. to derive the p-value of gene g. This added variable selection avoids includ-
ing more than one study-specic variable in the model and allows assessment of biomarkers
related to dierent study-specic variable ( e.g. gene A might be related gender while gene
B might be related to brain region or platform), which biologically gives a more appealing
conclusion and interpretation. These attached p-value numbers are, however, not the real
p-values for DE gene detection since they are biased from the variable selection procedure.
As a result, we perform a permutation test that randomly permutes the disease labels within
each pair to generate a null distribution eect sizes, then we repeat above variable selec-
tion procedure, and calculate the p-values, which server as the null distribution of p-values.
Subsequently, the resulting unbiased p-values can then be corrected by Benjamini-Hochberg
procedure for multiple comparisons for DE gene detection. Detailed algorithm of the per-
mutation analysis is described in Appendix A.
3.2.5 Post hoc analysis on study-level variables after meta-regression
An essential advantage of our gene-specic mete-regression with variable selection scheme is
the possibility of post hoc analysis on the selected study-specic variables in a genome-wide
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scale. Two questions can be explored and answered: (1) Which variable(s) is the most or
least frequently included in the model selection to inuence disease eect? (2) Are variables
repeatedly selected across genes more frequently than by random (e.g. sex is selected in
most or all genes)? For the rst question, we rst generated a list of DE genes under a
given FDR threshold and counted the frequency of each variable being selected in the gene
list. Higher frequency showed that the variable more frequently inuence the disease eects
in dierent genes. For the second question, permutation test was performed to assess the
statistical signicance of the observed frequency. Specically, suppose that we identied N
DE genes among which we observed variable X was selected N0 times. To generate the null
distribution for hypothesis testing, we randomly chose N genes from the entire genome and
count the frequency of variable X appearing in models associated with these genes as Nb.
By repeating B times, the p-value of of the observed frequency is p(X) =
PB
b=1 I(NbN0)
B
. We
use B=10000 in this paper.
3.2.6 Evaluation
To evaluate performance of dierent models and methods in a real data analysis, we compared
the number of detected DE genes among a specied set of MDD-related genes and performed
gene enrichment analysis using the same set of MDD-related genes, where the MDD-related
genes set was dened by web-tool (Gene Prospector: http://hugenavigator.net) by inputting
the search term, major depressive disorder. The search review produced 297 genes reported
with MDD among which 147 genes were included in our study. In addition, we identied
a set of 9 genes ("SST" , "VGF", "TAC1", "MBP", "MOBP", "RTN4", "QPRT", "DGCR2",
"EPHB6") that have been previously associated with MDD in the literature, but not in-
cluded in the data base of Gene Prospector. For gene enrichment analysis, we performed
Kolmogorove-Smirnov (KS) test, which was widely used in gene enrichment analysis [61, 91]
because it is sensitive to dierences in both location and shape of the empirical cumulative
distribution functions of the two samples. Specically, the p-values calculated from individ-
ual analyses or meta-analyises for assessing the DE genes are classied into two categories,
in the specied MDD-related gene set (P ) and out of pathway (PC). Let p(1); p(2);    ; p(n)
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and ~p(1); ~p(2);    ; ~p(m) denote the order statistics of the p-values in P and PC , respectively.
The corresponding empirical distribution functions, F^P (x) and F^PC (x) for P and P
C can be
dened as:
F^P (x) =
8>>>>><>>>>>:
0; if x < p(1)
k
n
; if p(k)  x < p(k+1) k = 2; 3;    ; n  1
1; if x  p(n)
(3.10)
and
F^PC (x) =
8>>>>><>>>>>:
0; if x <  ~p(1)
k
m
; if ~p(k)  x < ~p(k+1) k = 2; 3;    ;m  1
1; if x  ~p(n)
(3.11)
Let FP and FPC denote the population distribution for P and P
C , respectively. The
one-sided two sample KS test can be dened based on the formula:
TKS = max
x
[Fp(x)  FPC (x)]; (3.12)
where the null hypothesis and the alternative hypothesis are :
H0 : FP (x) = FPC (x) for all x (3.13)
Ha : FP (x)  FPC (x)for all x (3.14)
&FP (x) > FPC (x)for some x (3.15)
Under the null hypothesis, the rejection region has the form of TKS > C at level of .
Rejection of H0 means that P is stochastically less than P
C (the CDF of P lies above and
hence to the left of that for PC). In another words, the p-values of genes in the genes set P
are stochastically less than the p-values of genes outside of gene set PC. This indicates that
genes in the pathway P have a stronger association with MDD than genes from outside of
the gene set PC . Small p-value associated with KS test indicates a good performance of the
methods.
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3.3 RESULTS
3.3.1 Fixed eect model and Random eect model
We applied the chi-squared test using a Q-statistic proposed by Cochran [18] to assess homo-
geneity of the studies. Under the hypothesis of homogeneity, if follows a 2K 1 distribution.
A large deviation of observed Q statistic relative to the null distribution indicates rejection of
the hypothesis of homogeneity, which therefore a random eect model is more appropriate.
Although this test is known to have low statistical power [42], the result shows that the
heterogeneity exits among 3594 genes after controlling FDR at 5%. The previous method
is based on gene by gene test. To further conrm the existence of the heterogeneities , we
assume that the genes can be treated as independent samplings and the homogeneity can be
explored over all the genes. The histogram of the observed Q values and quantile-quantile
plot (Q-Q plot) of the observed versus expected values are shown in Figure 3.1. The sample
mean and variance of Q values are 17 and 114, respectively, which are much larger than that
of the expected mean and variance, 7 and 14 and argue overall heterogeneity of the studies
in meta-analysis.
3.3.2 comparing individual analysis and meta-analysis
Among the many microarray meta-analysis methods used in the literature, most methods
have their pros and cons depending on the data structure and biological goal [47, 78]. In
this paper, although we mainly focused on comparing REM and MetaRG, we also included
the results of Fisher's method since it has been popularly applied in the microarray meta-
analysis literature. Figure 3.2 showed the DE number plots of both meta-analysis results
and compared with individual study analyses under various FDR thresholds. The exact DE
numbers were listed in Table 3.1, and the result shows that individual study results had
very weak signal and meta-analysis improved the statistical power and provided validated
conclusions.
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Figure 3.1: Gene by gene testing for the homogeneity of study eects. Overall test results
are shown by the histogram of the observed Q values and the plot of the observed versus
expected Q quantiles for the 8 MDD studies
3.3.3 Comparing REM and MetaRG
REM versus MetaRG: MetaRG detects both consistent markers that REM can detect and
also markers confounded by study-level variables that REM cannot detect. MetaRG detects
more markers than REM in general. A Venn diagram of DE gene lists detected by REM
and MetaRG methods under FDR=1% is shown in Figure 3(a). The result showed that the
three meta-analysis methods detected dierent sets of DE genes. Furthermore, in Figure
4(b), we drew the density plot of q-values calculated by MetaRG method for those 73 DE
genes detected by REM only and the density plot of q-values calculated by REM method for
those 175 DE genes detected by MetaRG only, the result shew that almost all genes detected
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Table 3.1: Results of individual study analyses and meta-analysis
C
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1
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M
D
2
A
C
C
M
M
D
1
A
M
Y
F
M
D
2
M
D
2
D
L
P
F
C
F
M
D
3
A
C
C
F
C
M
D
2
A
C
C
F
M
D
3
A
M
Y
F
F
is
h
er
R
E
M
(I
V
W
)
M
et
aR
G
p=0.001 30 12 28 5 79 26 22 113 394 116 139
p=0.005 186 50 144 42 292 131 107 391 997 241 339
FDR=0.05 0 0 0 0 4 0 0 0 1307 103 124
FDR=0.1 0 0 0 0 97 1 0 406 2407 167 269
by REM can be detected by MetaRG if the FDR threshold is slightly relaxed. But many
genes detected by MetaRG cannot be detected by REM. For example, Figure 2 shows the
forest plot of an example gene SST (somatostatin; a gene known to aect neurotransmission
in the central nervous system). When using conventional random eect (REM) model, the
p-value is marginally signicant (p=0.01) and the gene cannot be detected after multiple
comparison. The forest plot shows a clear pattern that female MDD patients generally have
down-regulation in SST while males have only slight down-regulation. Another example,
Figure 3 shows the forest plot of an example gene ELP3 ( elongation protein 3 homolog;
a gene known to regulate the maturation of projection neurons). When using conventional
random eect (REM) model, the p-value is marginally signicant (p=0.02) and the gene
cannot be detected after multiple comparison. The forest plot shows a clear pattern that
this gene generally have down-regulation in AMY brain region while have slight up-regulation
in ACC and DLPFC brain region.
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Figure 3.2: The DE number plot of both meta-analysis and individual analyses under various
FDR thresholds.
Fisher: the most sensitive but can be tricky. Powerful for virtually all kinds of potential
markers but may also contain many false positives. Can detect: (1) most of genes detected
by REM (2) many of the genes detected by meta-regression (3) genes confounded unknown
factors that can not be explicitly identied by meta-regression.
3.3.4 Frequencies of study-level covariates confounded with disease eect
MetaRG not only detects more biomarkers than REM by including biomarkers confounded by
study-level covariates, but also has the advantage of showing the overall impact (frequency)
of a study-level covariate confounded with the disease eect in the genome. One of MetaRG's
potential abilities is to work out whether particular characteristics of studies are related to
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Figure 3.3: (a) the venn diagram of DE gene lists detected by REM and MetaRG at FDR
1%. (b) the density plot of q-values calculated from MetaRG for three categorical sets of
DE genes.(c) The density plot of q-values calculated from REM for three categorical sets of
DE genes
the eect sizes or not. To evaluate the impact of each characteristic of studies on the disease
eect, especially among DE genes, we counted the numbers of appearances of study-specic
variables in the meta-regression models for DE genes detected by MetaRG method under
various p-value or FDR thresholds (see Table3.1). For example, under FDR=0.1 threshold,
among which, 146 were sex-dependent markers, 37 were brain-region-dependent, and 39
were array-platform dependent. The p-values for testing whether sex, brain region and array
platform are selected more frequently than by random are 0, 0.04 and 0.2, respectively, which
indicates that sex is more frequently to inuence the MDD eect, especially, among those
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Figure 3.4: (a) the forest plot of gene SST. (b) the forest plot of gene ELP3.
DE genes. The wider spread of sex-dependent candidate markers provides an opportunity
to investigate why women are more vulnerable to MDD than men [55].
3.3.5 Result of Komogorv-Smirnow test
To further evaluate the performance of individual analysis and three meta-analysis meth-
ods, Figure3.5 showed the number of MDD-related genes detected from meta-analysis and
from individual study analyses under various FDR thresholds. The results showed again
that MeteRG method could detect more MDD-related genes than REM method, and Fisher
method detected much more MDD-related genes than REM and MetaRG because because
there might be many unidentiable confounders (surrogate variables) that Fisher could cap-
ture. The result of KS test was shown in Table 3, which showed that overall the performance
62
0.00 0.02 0.04 0.06 0.08 0.10
0
10
20
30
40
50
60
FDR cut−off
Sig
nifi
can
t te
sts
C_MD2_DLPFC_M
MD1_ACC_M
C_MD2_ACC_M
MD1_AMY_M
C_MD2_DLPFC_F
MD3_ACC_F
C_MD2_ACC_F
MD3_AMY_F
Fisher
REM
MetaRG
Figure 3.5: The number of genes detected from both meta-analysis and individual analyses
among 156 MDD-related genes under various FDR thresholds.
of meta-analysis was better than that of individual analysis. Among three meta-analysis
methods, Fisher and MetaRG had the similar performance which was better than that of
REM.
3.4 DISCUSSION AND CONCLUSION
In this paper, we applied the meta-regression model on 8 MDD microarray studies, and
compared it with the random eect model (REM) often used in gene expression analysis.
The results showed that the meta-regression model gain some power of DE gene detection
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by considering the heterogeneity potentially introduced by the three study-specic variables
(i.e. sex, brain-region and array platform). More importantly, the meta-regression model
has the potential ability to identify the biomarkers related to some study-specic variables,
such as gene SST may be related to sex and gene ELP3 may be related to brain region.
A common situation in genomic study is that there are few studies in a meta-analysis
but many possible study-level variables that might explain heterogeneity. In this situation,
careful selection of appropriate covariates for inclusion into a meta-regression analysis is
imperative for getting trustworthy results. In this paper, we proposed a meta-regression
model with variable selection in which we allowed at most one study-level variable to be
included in the meta-regression model. This provide a unied procedure to deal with the
problem encountered in above situation. One of advantages of the meta-regression with
variable selection is to biologically give a more appealing conclusion and interpretation,
compared the univariate meta-regression, where we have a dicult to interpret the results
after carrying out three mete-regressions with only one of three study-level variables. For
example, based on the adaptive weights for each gene, we can gure out whether the eect
sized is inuenced by some specic variables.
In this paper, we compared three meta-analysis methods. Suppose that the heterogeneity
can be totally explained by at least one of three study-level variables, MetaRG should yield
the best result compared Fisher and REM methods. However, in this genome setting, Fisher
yielded the better results in both DE gene detection and gene enrichment analysis than
MetaRG and REM because because there may be many unidentiable confounders (surrogate
variables) that Fisher can capture. Therefore, a future direction is to explore methods to
adjust the heterogeneity introduced by some surrogate variables, such as latent variable
methods and surrogate variable analysis (SVA) proposed by Leek[38].
64
4.0 METADE: A R PACKAGE TO PERFORM META-ANALYSIS FOR
DIFFERENTIAL EXPRESSION ANALYSIS
4.1 INTRODUCTION
Many high-throughput genomic technologies have advanced dramatically in the past decade.
Microarray experiment is one example that evolved into relative maturity with generally
consensus experimental protocol and data analysis strategy. Its extensive application in the
biomedical eld has led to an explosion of gene expression proling studies publicly available.
The noisy nature and small sample size in each dataset, however, often result in inconsistent
biological conclusions [28, 92, 107]. Consequently, meta-analysis methods for combining mi-
croarray studies have been widely applied to increase statistical power and provide validated
conclusions. Four major categories of statistical methods have been used to combine microar-
ray studies in dierentially expressed (DE) gene detection: combining p-values[52, 79, 80],
combining eect sizes[15, 66], combining ranks [21, 48]and directly merge after normaliza-
tion. In the "combining p-value" category, Fisher's method was the rst analytical method
applied to microarray meta-analysis. Other methods such as Stouf-fer, minimum p-value
(minP), maximum p-value (maxP), rth ordered p-value (rOP), adaptively weighted Fisher
(AW) and vote counting have also been widely used. In the category of 'combining eect
sizes", there are two major types of statistical analysis: xed and random eects models.
For example, Choi et al (2003) combined eect sizes using weighted estimate for individual
genes based on the xed or random eects models Detailed description and comparison are
given in section 1.4. In the category was initially proposed to detect dierentially expressed
genes for a single experiment (Breitling et al., 2004). Our package provides functions that
perform most commonly used classical methods in each category as well as the proposed
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methods from our group,such s AW method, roP methods and three meta-analysis methods
with one-sided correction (minP OC, maxP OC, and roP OC) which were given more detail
description in subsection 4.1.1.
Despite the popularity of meta-analysis in microarray data, no comprehensive software
package exists to date for easy implementation and comparison. Existing packages usually
only provide limited functions to perform one or two methods; examples include GeneMeta
(implements xed and random eects models), metaMA (implements random eects model
and Stouer's method), metaArray (implements meta-analysis of probability of expression,
POE), OrderedList (compares ordered gene lists), SequentialMA (determines sensitivity and
decides whether more samples are needed to assure rm conclusion), RankProd (implements
rank product method) and RankAggreg (implements various advanced rank aggregation
methods). Methods implemented in the above packages mostly focus on binary outcomes
and are not applicable to general continuous, multi-class and time-to-event outcomes. When
applied to a specic microarray meta-analysis project, dierent algorithms generate dierent
top ranked DE genes and q-values. Hong et al.[47] and Campain and Yang [13] are, by
far, the only two comparative studies that evaluated the results of dierent meta-analysis
algorithms. The included methods, tested examples and resulting conclusions in these two
papers are, however, not yet conclusive enough to guide applications. It is very helpful that
one can easily implement various methods for further comparison, assessment and selection
to present results of all of the dierent methods. As a result, we developed the MetaDE
package to provide comprehensive method selection, exible while unied data input for-
mats, options of dierent outcome types, various test statistics for DE analysis and choice
of p-value calculation by fast parametric or robust permutation inferences. The goal is to
provide a hands-on implementation of a given microarray meta-analysis project and easy
evaluation and comparison of the results by dierent analytical methods. The computation
is optimized by embedded C code and the open-source R environment allows extensibility
for added features or methods in the future.
66
4.1.1 Meta-analysis methods with one-sided correction
Comparing the rst two categories of meta-analysis methods in Section 1.4.1 and Section
1.4.2, combining eects sizes (e.g. random or xed eects model) automatically identies
genes that have consistent up- or down-regulation in all studies. This may not be the case
for methods combining p-values if the p-values are obtained from two-sided hypothesis test-
ing. In this case, up- and down-regulation are treated as equally strong evidence and a gene
may be detected from the meta-analysis with strong up-regulation evidence in one study
but strong down-regulation evidence in another study, which leads to confusing conclusions.
Theoretically, the discordance may reect underlying biological truth due to population het-
erogeneity. In practice, however, such concordances are mostly results of technical artifacts
such as gene annotation mistakes or cross-hybridization. A convenient solution to avoid
the concordances is to generate p-values or ranks by one-sided tests. Owen [75] applied
a similar Pearson one-sided test adjustment for Fisher's method. One-sided correction is
helpful to guarantee identication of DE genes with concordant DE regulation directions.
In this dissertation, we extended this modication to minP, maxP and roP methods which
are described in following sub-sections. Under null hypothesis, the analytical cumulative
distribution functions (CDF) of these three methods were derived (see Appendix D). Note
that the consistent up- or down-regulation issue only exists in two-class comparison in DE
gene detection and does not apply to other types of response variables (e.g. multi-class,
continuous or survival).
4.1.1.1 Notations For gene g and study k, we let gk denote the eect of MDD. The
Null hypothesis for gk is H0 : gk = 0. Then, for k = 1; 2;    ; K, we can consider the
hypotheses:
H0;gk : gk = 0
HL;gk : gk < 0
HR;gk : gk > 0
67
and
HU;gk : gk 6= 0;
based on the sign of gk. These are the null hypotheses, left- and right-sided alternatives
and an undirected alternative, respectively.
Using ^obsgk as test statistics, we may dene
~pgk = Pr(^gk  ^obsgk jgk)
and
pgk = Pr(j^gkj  j^obsgk jjgk = 0)
The p values for alternatives HL;gk, HR;gk and HU;gk, respectively, are ~pgk, 1   ~pgk and
pgk = 2min(~pgk; 1  ~pgk).
4.1.1.2 Pearson's method(Fisher OC) To guarantee identication of DE genes with
concordant DE direction, Owen [75] revisited Pearson's method[77] and showed that Pear-
son's method has proved useful in a genomic setting[105], screening for age-related genes.
Let ~pgk denote the p-value for the test of left-sided alternative in study k(1  k  K).
QLg =  2 
PK
k=1 ln ~pgk (4.1)
QRg =  2 
PK
k=1 ln(1  ~pgk) (4.2)
Then, the test statistic of Pearson is dened as
V Fisher OCg = maxfQLg ; QRg g (4.3)
Under null hypothesis, the distribution of V Fisher OCg can not be derived analytically. A
conservative p-value was suggested by Owen.
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4.1.1.3 minP method with one-sided correction(min OC) From hereafter, we will
omit the subscript g. Under the null hypothesis,~pk , 1   ~pk and pk all have the U(0; 1)
distribution. It follows that
QminPL = minf~p1; ~p2;    ; ~pKg (4.4)
QminPR = minf1  ~p1; 1  ~p2;    ; 1  ~pKg (4.5)
and
QminPU = minfp1; p2;    ; pKg (4.6)
All have the Beta(1; K) distribution under H0.
Then, the one-sided test statistic is dened as
QminPC = min(Q
minP
L ; Q
minP
R ) (4.7)
Theorem 4.1.1. If ~p1;    ; ~pK independently and identically follow U(0; 1) distribution, then
the cumulative distribution function (CDF) of statistic QminPC is given by
G(z) =
8><>:1  (1  2z)
K ; if 0  z  0:5
1; if 0:5  z  1
(4.8)
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4.1.1.4 maxP method with one-sided correction (maxP OC) Similarly, Let ~pgk
denote the p-value for the test of left-sided alternative in study k(1  k  K).
QLg = max1kK ~pgk (4.9)
QRg = max1kK(1  ~pgk) (4.10)
Then, the test statistic of maxP OC is dened as
QmaxP OCg = minfQLg ; QRg g (4.11)
Under null hypothesis, the p-value associated with QmaxP OCg can be assessed by the following
Theorem, which is proved in AppendixD.
Theorem 4.1.2. If ~p1;    ; ~pK independently and identically follow U(0; 1) distribution, then
the cumulative distribution function (CDF) of statistic QmaxP OCg is given by
F (z) =
8><>:2z
K ; if 0  z < 0:5
2zK   (2z   1)K ; if 0:5  z  1
(4.12)
4.1.1.5 roP method with one-sided correction(roP OC) Similarly, Let ~pgk denote
the p-value for the test of left-sided alternative in study k(1  k  K).
QLg = pg(r)f~p1; ~p2;    ; ~pKg (4.13)
QRg = pg(r)f1  ~p1; 1  ~p2;    ; 1  ~pKg (4.14)
(4.15)
Then, the test statistic of roP OC is dened as
V roP OCg = minfQLg ; QRg g (4.16)
Under null hypothesis, the p-value associated with V roP OCg can be assessed by the following
Theorem.
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Theorem 4.1.3. If ~p1;    ; ~pK independently and identically follow U(0; 1) distribution, then
the cumulative distribution function (CDF) of statistic V roP OCg is given by Case1: r 
K   r + 1.
F (z) =
8><>:2(1  F (r   1; K; z)); if 0  z < 0:51 Pr 1j=K r+1PK jh=K r+1 K!j!h!(K j h)!(1  z)j+h(2z   1)K j h; if 0:5  z  1(4.17)
(4.18)
Case2: r < K   r + 1
F (z) =
8><>:1 
Pr 1
l=0
Pr 1
m=0
K!
l!m!(K l m)!z
m+l(1  2z)K l m; if 0  z  0:5
1; if 0:5  z  1
(4.19)
4.2 IMPLEMENTATION
MetaDE package implements 12 major meta-analysis methods for dierential expression
analysis: Fisher, Stouer, adaptively weighted Fisher (AW), minimum p-value (minP), max-
imum p-value (maxP), rth ordered p-value (rOP), vote counting, xed eects model (FEM),
random eects model (REM), rank product (rankProd), nave rank sum/product and meta-
analysis adjusted for confounding variables (MetaACV) (Table 4.1). Detailed algorithms,
their restrictions and general pros and cons are discussed in the online supplement doc-
ument. In addition to selecting a meta-analysis method, several other considerations are
involved in the implementation. (1) Choice of test statistics: Multiple test statistics are
available for each type of outcome variable. For multi-class outcomes, the minimum multi-
class correlation (min-MCC) was particularly developed to capture concordant expression
patterns that F-statistics can fail [50]. (2) One-sided correction: For binary outcomes, DE
genes with discordant regulations (e.g. up-regulation in one study but down-regulation in
another study) can often be identied if two-sided p-values are to be combined and the re-
sults are dicult to interpret. One-sided correction that was considered by Pearson (1938)
is helpful to guarantee identication of DE genes with concordant DE regulation directions.
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Figure 4.1: Summary of 12 microarray meta-analysis methods included.
(3) Adjustment for confounding variables: Clinical or technical variables (e.g. gender, race
etc) can be important confounders that aect sen-sitivity of DE gene detection. We have
adopted the Meta-Analysis Adjusted for Confounding Variables (meta-ACV) with eective
gene-specic variable selection [100] and applied the approach to all p-value combination
methods and all outcomes except for multi-class variables. MetaDE takes two types of uni-
ed input formats: standard Ex-pressionSet objects from Bioconductor or lists of ordinary
data matrixes in R. Options of gene matching across studies and gene ltering are available.
Missing values are allowed if a gene is miss-ing in partial studies. Outputs of the meta-
analysis results include DE gene lists with corresponding q-values and various visualization
tools. A technical document, a tutorial and R help les are available online, accompanying
the package.
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4.2.1 Data pre-processing
Gene matching: Usually dierent microarray platforms use their own probe IDs. To perform
metan-analysis, we need match probe IDs from dierent platforms to the unique ocial gene
ID, such as ENTREZ ID or gene symbol. In this package, we focus on the gene symbol. In
MetaDE package, we provide two options to match probe ID to gene symbol when multiple
probes (or probe sets) matched to an identical gene symbol: one is average method in which
we take the average value of expression values among multiple probe IDs to represent the
corresponded gene symbol; another one is "IQR" method in which we selected the probe
ID with the largest interquartile range (IQR) of expression values among all multiple probe
IDs to represent the corresponded gene symbol. The procedure of gene matching can be
implemented by function Match.gene(). The arguments of this function are
Match.gene(x,pool.replicate=c("average","IQR"))
where x is an eSet (Container for high-throughput assays and experimental metadata), and
one column named by "GENESYMBOL"of featureData of x must include the gene symbols.
The arguments for pool.replicate are then:
• "average": the average method mentioned as above was chosen to perform gene match-
ing;
• "IQR": the "IQR"method mentioned as above was chosen to perform gene matching;
Gene ltering: If we hold an enormous number of Genes, thus raise many practical and
theoretical problems in controlling the false discovery rate(FDR). Biologically, it is likely
that most genes are either un-expressed or un-informative. In gene expression analysis to
nd DE genes, these genes contribute the false discoveries, so it is desirable to lter out
these genes prior to analysis. After genes were matched across ve studies, the unique gene
symbols were available across all studies. Two sequential steps of gene ltering were then
performed. In the rst step, we ltered out genes with very low gene expression that were
identied with small average expression values across majority of studies. Specically, mean
intensities of each gene across all samples in each study were calculated and the corresponding
ranks were obtained. The sum of such ranks across all studies of each gene was calculated
and genes with the highest % rank sum were considered un-expressed genes (i.e. small
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expression intensities) and were ltered out. Similarly, in the second step, we ltered out non-
informative (small variation) genes by replacing mean intensity in the rst step with standard
deviation. Genes with the lowest % rank sum of standard deviations were ltered out.
Finally, the total number of matched genes is G(1 )(1 ), which are used for further
analysis. The procedure of gene ltering can be implemented by function Gene.filter. The
arguments of this function are
Gene.filter(x,DelPerc=c(alpha,beta)),
where x is the input variable,which is a list of a list datasets and a list of labels; argument
DelPerc is a numeric vector of length 2, which specify how many percent of genes need to
be ltered out during the two sequential steps of gene ltering.
4.2.2 Perform individual analysis
Before beginning with a meta-analysis, one must rst obtain a set of p-values or eect
size estimates with their corresponding sampling variances.The MeteDE package provides
the ind.analysis() function, which can be used to perform various test statistics for DE
analysis based on the type of the outcome and choice of p-value calculation by fast parametric
or robust permutation inferences.For the default interface, the arguments of the function are
ind.analysis(x,ind.method=c("regt","modt","pairedt","pearsonr","spearmanr",
"F"), nperm,tail,...)
where x is the input variable,which is a list of a list datasets and a list of labels; argument
ind.mehtodis a character string specifying which test statistic should be used to calculated
the p-values.The options for argument ind.method are then:
• regt: The regular t-statistics.
• modt: The moderated-t statstics.
• pairedt: The paired t-statistics.
• pearsonr: The Pearson product correlation statistics.
• F: The F-statistics.
• spearmanr: The Spearman rank correlation statistics.
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nperm is an argument to specify the choice of p-value calculation by fast parametric or
robust permutation inferences. If it is NULL(default), the parametric method is used; If it is
an integer, the permutation method is used, and the integer is the number of permutations
used to infer the p-values. tail is a character string specifying the direction of alternative
hypothesis , must be one of "low"(left-side p-value), "high"(right-sided p-value) or "abs"(two-
sided p-value).
The MetaDE package also provides an function cal.ES to calculate various eect sizes
(and the corresponding sampling variances) that are commonly used in meta-analyses.The
arguments for this interface are
cal.ES(y,l,paired=FALSE)
where arguments yand l are the gene expression matrix and the vector of labels of outcome,
respectively; paired is a logical indicating whether the experiment is paired design or not,
and then the eect sizes(and corresponding sampling variances) are calculated. The output
of this function is an matrix including the biased and unbiased eect size estimates (and
corresponding variances) (see section 1.4.2).
4.2.3 Perform meta-analysis
The various meta-analyses can be implemented by three main functions,MetaDE.radata(),
MetaDE.pvalue() and MetaDE.ES(), in MetaDE package. The arguments of function
MetaDE.radata() are given by
MetaDE.rawdata(x, ind.method=c("modt","regt","pairedt","F","pearsonr",
"spearmanr","logrank"),meta.method=c("maxP","maxP.OC","minP","minP.OC",
"Fisher","Fisher.OC","AW","AW.OC","roP","roP.OC","vote","vote.OC",
"minMCC","rankProd","naiveranksum"),rth=NULL,nperm=NULL,ind.tail="high"
,asymptotic=FALSE,...)
As above,x is the raw data (the gene expression matrices and the labels of outcome),which is
a list of a list datasets and a list of labels; the argument ind.method is the same as that in
function ind.analysis(); The various meta-analysis methods described in section 1.4 that
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can be specied via the meta.method argument are then:
• maxP: The maximum p-value method;
• maxP.OC: The maximum p-value with one-sided correction;
• minP: The minimum p-value method;
• minP.OC: The minimum p-value method with one-sided correction;
• Fisher The Fisher's method;
• Fisher.OC: The Fisher's method with one-sided correction;
• AW: The adaptive weight method;
• AW.OC: The adaptive weight method with one-sided correction;
• roP: The r-th ordered p-value method;
• roP.OC: The r-th ordered p-value method with one-sided correction;
• vote: The vote counting method;
• vote.OC: The vote counting method with one-side correction;
• minMCC: The the minimum multi-class correlation method [50];
• rankProd: The rank product method [48];
• naiveranksum":The naive rank summation method;
If themeta.method is chosen as "roP"or "roP.OC", an integer need input via argument rth
to specify which rth ordered p-value as the statistic; If the argument asymptotic is TRUE,
then the parametric method is used in meta-analysis to calculate the p-values; the argument
nperm is the same as in function ind.analysis().
If p-values or eect sizes (and corresponding variances) have been calculated already, for
example by other methods not used in functions ind.analysis() or cal.ES() with the help
of other software, then the meta-analysis can be implemented by function MetaDE.pvalue()
or MetaDE.ES(). The arguments of these two functions are given by
MetaDE.pvalue(x,meta.method=c("maxP","minP","Fisher","Pearson","Stouffer",
"roP","AW","maxP.OC","roP.OC"),asymptotic=FALSE)
, where argument x is a list whose rst object is the p-value matrix,and second object are
the permutated matrices. If the second object of x is NULL, the parametric method is then
used in meta-analysis.
76
MetaDE.ES(x,paired=FALSE,REM=TRUE,correct=TRUE)
, where xis the raw data (the gene expression matrices and the labels of outcome),which is
a list of a list datasets and a list of labels; argument paired is a logical indicating whether
the studies are paired design or not; argument REM is a logical specifying whether a xed-
or a random/mixed-eects model(default) should be tted. Random/mixed-eects models
are tted by using "DL"method to estimate the between-study variance(see 1.4.2).
4.2.4 Draw plots
The MetaDE package provides several functions for creating plots that are frequently used in
meta-analyses.For example,the heatmap.sig.genes() function is used to create the Heatmaps
plots of the DE genes under some p-value or FDR threshhold across studies; The forestplt()
is use to darw the Forest plots of selected genes can be generated for binary outcomes; the
draw.DEnumber() function is used to generate the DE number plots (a plot showing the num-
ber of detected DE genes under dierent p-value or q-value threshold) can be shown to com-
pare sensitivity in individual study analyses and dierent meta-analyses methods. To view
the exact number of DE genes detected by dierent methods, the function count.DEnumber()
can be used to generate the tables in which the numbers of DE genes detected by dierent
methods under various p-value and FDR thresholds are listed. Several examples are given
in next section to illustrate how such plots can be created.
4.2.5 EXAMPLE
To demonstrate the functionality of MetaDE, we performed meta-analysis to combine 4 major
depressive disorder (MDD) studies. We present the results of maxP without confounder
adjustment (Figure )under p-value threshold 0.001.The Figure was created with the following
code.
>maxP.pt<-MetaDE.rawdata(x,ind.method="pairedt",meta.method="maxP",
ind.tail="abs",asymptotic=TRUE)
> heatmap.sig.genes(maxP.pt,pval.cut=0.001)
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Figure 4.2: The heatmap of DE genes detected by maxP method under p-value threshold
0.001 based result of paired t-test in individual analysis.
Figure 4.3(A) and (B) shows the DE number plots of both meta-analysis results and
compared with individual study analyses. The result shows that individual study results
had very weak signal. Meta-analysis improved the statistical power and provided validated
conclusions.The Figures were created with the following code.
#Figue (A)
minP.pt<-MetaDE.rawdata(x,ind.method="pairedt",meta.method="minP",
ind.tail="abs",
asymptotic=TRUE)
fisher.pt<-MetaDE.rawdata(x,ind.method="pairedt",meta.method="Fisher",
ind.tail="abs",
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asymptotic=TRUE)
stouf.pt<-MetaDE.rawdata(x,ind.method="pairedt",meta.method="Stouffer",
ind.tail="abs",
asymptotic=TRUE)
REM.pt<-MetaDE.ES(x,paired=TRUE,REM=TRUE,correct=TRUE)
pm.pt<-cbind(maxP.pt$ind.p,maxP.pt$meta.analysis$pval,
fisher.pt$meta.analysis$pval,REM.pt$pval)
method<-c(c("MD1_ACC_M","MD3_ACC_F","C_MD2_ACC_F","C_MD2_ACC_M",
"maxP","Fisher","REM"))
mlwd<-rep(c(2,4),c(4,4))
#Figue (B)
x<-list()
x$p<-p.m[,c("MD1_ACC_M","MD3_ACC_F","C_MD2_ACC_F","C_MD2_ACC_M")]
x$bp<-NULL
maxP.acv<-MetaDE.pvalue(x,meta.method="maxP",asymptotic=T)
fisher.acv<-MetaDE.pvalue(x,meta.method="Fisher",asymptotic=T)
ES.acv<-ES.m[,c("MD1_ACC_M","MD3_ACC_F","C_MD2_ACC_F","C_MD2_ACC_M")]
Var.acv<-Var.m[,c("MD1_ACC_M","MD3_ACC_F","C_MD2_ACC_F","C_MD2_ACC_M")]
REM.acv<-get.REM(ES.acv,Var.acv)
pm.acv<-cbind(x$p,maxP.acv$pval,fisher.acv$pval,REM.acv$pval)
method<-c(c("MD1_ACC_M","MD3_ACC_F","C_MD2_ACC_F","C_MD2_ACC_M","maxP",
"Fisher","REM"))
mlwd<-rep(c(2,4),c(4,4))
count.DEnumber(pm.acv,c(0.001,0.005),c(0.01,0.05,0.1),method)
#draw Figure
par(mfrow=c(1,2))
draw.DEnumber(pm.pt,0.005,0.004,method,mlwd)
title("(A) Paired t-test")
draw.DEnumber(pm.acv,0.005,0.004,method,mlwd)
title("(B) MetaACV")
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We also can use count.DEnumber() function to list the exact number of DE genes under
various p-value or FDR thresholds. For example, the tables can be created by the following
code:
> #paired t-test
> count.DEnumber(pm.pt,c(0.001,0.005),c(0.01,0.05,0.1),method)
$pval.table
MD1_ACC_M MD3_ACC_F C_MD2_ACC_F C_MD2_ACC_M maxP Fisher REM
p=0.001 2 14 8 23 155 73 13
p=0.005 22 85 52 154 425 291 59
$FDR.table
MD1_ACC_M MD3_ACC_F C_MD2_ACC_F C_MD2_ACC_M maxP Fisher REM
FDR=0.01 0 0 0 0 0 0 0
FDR=0.05 0 0 0 1 169 5 0
FDR=0.1 0 0 0 3 572 96 0
> #MetaACV
> count.DEnumber(pm.acv,c(0.001,0.005),c(0.01,0.05,0.1),method)
$pval.table
MD1_ACC_M MD3_ACC_F C_MD2_ACC_F C_MD2_ACC_M maxP Fisher REM
p=0.001 12 26 22 28 122 90 71
p=0.005 50 131 107 144 323 301 169
$FDR.table
MD1_ACC_M MD3_ACC_F C_MD2_ACC_F C_MD2_ACC_M maxP Fisher REM
FDR=0.01 0 0 0 0 3 0 7
FDR=0.05 0 0 0 0 72 8 36
FDR=0.1 0 1 0 0 264 171 65
In the on-line technical document, we presented two other examples: prostate cancer
studies (multi-class outcome) and breast cancer (survival outcome).
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Figure 4.3: (A)The DE number plot of paired t-test.(B) The DE number plot of MetaACV.
4.3 DISCUSSION AND CONCLUSION
The MetaDE package provides a wide collection of classical and emerging meta-analysis
methods for identifying DE genes. Comparing to other packages, MetaDE oers much wider
options of analysis methods for both individual dataset analysis and meta-analysis. It is
suitable to researchers who want to easily obtain an analysis and tailor their choices to
the biological questions of interest. For example, if one is interested in nding genes that
are dierentially expressed between cases and controls in all datasets. One could select
"moderated t-test" from the individual analysis and select "maxP" from the meta-analysis
to combine the p-values for moderated t-test. This would form the "modt+maxP" method
for the whole process. One also could select "REM" as the meta-analytic method for this
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purpose. In this case, the eect sizes are generated during the stage of individual analysis
and they are combined through the REM as described in previous section. This setting is
highly suitable for those who want more exibility. Moreover, a detailed online tutorial will
guide the user to make a choice on the methods that are suitable for their research questions.
Users should be aware of the limitations of the methods implemented in the MetaDE
package. First, the Bayesian approaches have not been implemented. Second, we assumed
that all studies contain identical matched gene list with no missing values. In real practice,
separate studies to be combined usually come from dierent microarray platforms. Requiring
an identical matched gene list and no missing values will exclude many important genes that
appear in certain studies but not in others, thus requiring an extension that allows for missing
values.
While we focused on combining multiple microarray studies in this paper, the package
can also be used to identify dierentially expressed biomarkers from similar data types, for
example, multiple genomic, epigenomic and/or proteomic datasets.
The MetaDE package provides R functions to perform meta-analysis for dierential ex-
pression analysis.
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5.0 CONCLUSIONS AND FUTURE WORKS
5.0.1 CONCLUSIONS
Meta-analysis or information integration of multiple genomic studies helps to increase sta-
tistical power of biomarker detection. However, the results of meta-analysis are easily biased
due to failure to incorporate important covariates at either the study or person level. For
example, in MDD studies, many clinical variables (sample-level or study-level), such as sex,
age, alcohol, antidepressant drug, or death by suicide, have been shown to be potential factors
characterizing subtypes of MDD. If the statistical models employed to identify dierentially
expressed genes fail to incorporate these sources of heterogeneity, not only can this reduce the
statistical power, but also it will introduce sources of spurious signals to the gene detection.
In this dissertation, rstly, we proposed a statistical approach for meta-analysis to tackle
weak signal expression proles that have small sample size, case-control paired design and
confounding covariates in each study. The results showed increased statistical power from
confounding variable adjustment, paired design modelling and meta-analysis in this genomic
setting and more profound biological ndings have been discovered in MDD neurobiology.
Secondly, to adjust the eect of study-level variables, we extended the idea of random eects
method and gene-specic variable selection to meta-regression (MetaRG) approach, which
has an appealing property to identify confounded study-level covariates and obtain a more
accurate disease eect size after adjustment. To our knowledge, this is the rst systematic
investigation in this area, which systematically considers the critical elements in the data
structure in order to obtain more accurate DE gene and pathway detection. The framework
is general and can be applied to microarray meta-analysis of other complex diseases with
similar data structure. Finally, we developed the MetaDE package to provide comprehen-
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sive method selection, exible while unied data input formats, options of dierent outcome
types, various test statistics for DE analysis and choice of p-value calculation by fast para-
metric or robust permutation inferences. This provided a hands-on implementation of a
given microarray meta-analysis project and easy evaluation and comparison of the results by
dierent analytical methods.
5.0.2 FUTURE WORKS
hierarchical meta-analysis model: MDD, Bipolar and Schizophrenia are three kinks of highly
correlated, but dierent, brain diseases. To study the linkage among these three brain dis-
orders,a biology question of interest is whether some genes are related to all of these three
diseases, or partially related to them. To addresse this question, we proposed a hierarchi-
cal meta-analysis model,which combines two complementary meta-analysis methods, rOp
and AW, to detect the biomarkers partially associated with MDD, Bipolar and Schizophre-
nia. The hierarchical meta-analysis is given in Figure 5.1. Specically,in Figure 5.2, we
illustrate how two meta-analysis designs might be combined for an integrated hierarchical
meta-analysis to detect biomarkers related to brain disorder subtypes. In the rst layer of
the hierarchical design, we combine studies with the same brain disease (MDD, Bipolar or
schizophrenia) and control samples using rOp or maxP method to get the consistent biomark-
ers associated with each disease. In the second layer, AW method is used to combine the
p-values obtained from the rst layer to identify biomarkers associated or partially associated
with these three brain disorders based on the adaptive weights. However, I did not get time
to carry out this investigation during during my Ph.D study. I will continue to nish this
project.
Evaluation of meta-analysis methods: Among the many microarray meta-analysis meth-
ods used in the literature, most methods have their pros and cons depending on the data
structure and biological goal. However,so far, there is no any rigorous criteria and method to
evaluate the performance of each method. Therefore, it will be very useful to develop some
methods to evaluate the performance of the meta-analysis methods.
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MDD Biploar Schizophrenia
RIM_minP FEM_minP FEM_minP
pv and ES pv and ES pv and ES
rOp rOp rOp
p−value p−value p−value
AW
Bimarker List
w=(w1,w2,w3)
categorezition
Biomarker List
Figure 5.1: The ow chart of a hierarchical meta-analysis.
Improvement of the MetaDE Package: The MetaDE package is developing. We need to
improve its functionality, for example, to include more methods in this package.
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1
D vs C
...
D vs C
K_1
D vs C
1
D vs C
...
D vs C
K_2
D vs C
1
D vs C
...
D vs C
K_3
D vs C
MDD Bipolar Schizophrenia
AW
rOp or maxP
Figure 5.2: The diagram of hierarchical meta-analysis.
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APPENDIX A
ALGORITHM OF PERMUTATION ANALYSIS
The procedure of permutation with minP variable selection method::
• Step1: For a give gene g, t all possible RIM (FEM) models that include at most r
(0,1,or r) clinical variables;
• Step2: Select the model RIM minP(FEM minP) with minimum p-value associated with
LRT for testing H0 : g0 = 0. Denote the resulting minimum p-values as p
(o)
g ;
• Step3: Permute the labels of disease and control within each pair (or among all samples)
B times. For the bth permutation, repeat step1-2 to get minimum
p-value, p
(b)
g (1  b  B; 1  g  G);
• Step4: The corrected p-value for gene g is calculated by
pg =
PB
b=1 I(p
(b)
g p(o)g )
B
1  b  B; 1  g  G),
where I(:) is an indicator function, which takes values ones when the statement is true
and zero otherwise.
Remark: Similarly, the above procedures can be used to correct the p-values associated
with the RIM BIC (FEM BIC) models. Note that BIC is used to choose the RIM BIC
(FEM BIC) models in step 2-3.
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APPENDIX B
ALGORITHM OF CONCORDANCE TEST
Procedure to test consistency of covariate eects in detected DE genes. We denote by eglk
the eect of covariate Xl(1  l  L) on the gene expression of gene g in the kth study if the
covariate is selected by RIM minP model selection. When covariate Xl is note selected by
RIM minP, eglk is not dened. Dene
Cgl(i; j) =
8>>>>><>>>>>:
1; if egli:eglj > 0
 1; if egli:eglj < 0
0; if egli or eglj is not dened
(B.1)
Cgl(i; j) takes value 1 if covariate Xl(1  l  L) appears in RIM minP modes in study i
and j, and both eects have the same direction (both positive or both negative). In this
situation, the eect Xl(1  l  L) in study i and j are consistent. On the contrary, Cgl(i; j)
takes value -1 when covariate Xl(1  l  L) appears in the RIM minP models in study i
and j, and have discordant eect sizes. When the covariate Xl(1  l  L) does not appear
in the RIM minP model of either study i or j, Cgl(i; j) takes value 0. To test whether the
covariates are selected by common covariates across studies more frequently than random,
we calculate the total number of times a covariate is selected by RIM minP among all pairs
of studies for a given gene set G
0
and denote as test statistics T1 below
T1(G
0
) =
X
g2G0
LX
l=1
X
1i<K
jCgl(i; j)j (B.2)
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To test the concordance of covariate eects across studies, we count only the concordant
cases in T1:
T1(G
0
) =
X
g2G0
LX
l=1
X
1i<K
I(Cgl(i; j) = 1) (B.3)
The concordance rate is then dened as R(G
0
) = T2(G
0
)=T1(G
0
). To test whether T1(G
0
) and
R(G
0
is larger than obtained by random with statistically signicance. Permutation analysis
below is performed:
Algorithm :Test the concordance::
• Step 1: Given a table of gene set G0 ,we calculate the observed statistics of T1(G
0
)
and R(G
0
) and denote them as T
(o)
1 and R
(o), respectively;
• Step 2: Randomly permute the observed (0,1,-1) values across clinical variables for
a given gene and a give study for B times. For each permuted data, calculate
the T1(G
0
) and R(G
0
) similarly to obtained T
(b)
1 and R
(b).
• Step 3: Calculate the p-values associated with T1(G
0
) and R(G
0
as pT1 =
PB
b=1 I(T
(b)
1 T (o)1 )
B
pR =
PB
b=1 I(R
(b)R(o))
B
.
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APPENDIX C
ALGORITHM OF META-REGRESSION ANALYSIS
Algorithm :to assess the p-value associated with MetaRG BIC::
• Step 1: Fit the RIM BIC models in each individual analysis, and estimate the observed
eect sizes Ygk and within-study variance 
2
gk.
• Step 2: Fit all the MetaRG models that include at most one (0 or 1) study-specic
variable,and then calculate the adaptive weight w, and then calculate the p-value
: P [Z(w)], denoted as p(o)
• Step 3: permute the MDD and control labels within each pair in each study. For bth
permutation, repeat step 1 and step 2. Denote the p-value in bth permutation as p
(b)
g
• Step 4: The resulting unbiased p-value for gene g is calculated as
pg =
PG
g
0
=1
PB
b=1 I(p
(b)
g p(o)g )
B
, where I(:) is an indicator function,
which takes value one when the statement is true and zero otherwise.
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APPENDIX D
THE PROOF OF ONE-SIDED CORRECTION METHODS
Theorem D.0.1. If ~p1;    ; ~pK independently and identically follow U(0; 1) distribution,
then the cumulative distribution function (CDF) of statistic QminPC is given by
G(z) =
8><>:1  (1  2z)
K ; if 0  z  0:5
1; if 0:5  z  1
(D.1)
Proof. Let ~p[r] denote the rth order statistics of ~p1;    ; ~pK . Then, we have
S = QminPL = ~p[1]
and
T = QminPR = 1  ~p[K]
Therefore, we have
X = ~p[1] = S
and
Y = ~p[K] = 1  T
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By theorem ??, we have the joint pdf of X and Y :
g(x; y) = K(K   1)(y   x)K 2
if 0 < x  y < 1, and zero otherwise. The Jacobian is J=-1, so the joint pdf of S and T is
given by
f(s; t) = K(K   1)(1  s  t)k 2 (D.2)
If 1  s  t > 0, 0 < s < 1 and 0 < t < 1, and zero otherwise.
Thus, we have
G(z) = Pr(QminPC  z)
= Pr(min(S; T )  z)
= 1  Pr(min(S; T ) > z)
= 1  Pr(S > z; T > z)
if 0 < z < 0:5
Pr(S > z; T > z) =
Z 1 z
z
Z 1 s
z
K(K   1)(1  s  t)K 2dtds
= (1  2z)K
if 0:5  z  1
Pr(S > z; T > z) = 0
Then, we have
G(z) =
8><>:1  (1  2z)
K ; if 0  z < 0:5
1; if 0:5  z  1
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Theorem D.0.2. If ~p1;    ; ~pK independently and identically follow U(0; 1) distribution,
then the cumulative distribution function (CDF) of statistic QmaxP OCg is given by
F (z) =
8><>:2z
K ; if 0  z < 0:5
2zK   (2z   1)K ; if 0:5  z  1
(D.3)
Proof. Let ~p[r] denote the rth order statistics of ~p1;    ; ~pK . Then, we have
S = QmaxPL = ~p[K]
and
T = QmaxPR = 1  ~p[1]
Therefore, we have
X = ~p[1] = 1  T
and
Y = ~p[K] = S
By theorem ??, we have the joint pdf of X and Y :
g(x; y) = K(K   1)(y   x)K 2
if 0 < x  y < 1, and zero otherwise. The Jacobian is J=-1, so the joint pdf of S and T is
given by
f(s; t) = K(K   1)(s+ t  1)k 2 (D.4)
If s+ t  1 > 0, 0 < s < 1 and 0 < t < 1, and zero otherwise.
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Thus, we have
G(z) = Pr(QmaxPC  z)
= Pr(min(S; T )  z)
= 1  Pr(min(S; T ) > z)
= 1  Pr(S > z; T > z)
if 0 < z < 0:5
Pr(S > z; T > z) =
Z 1 z
z
Z 1
1 s
K(K   1)(s+ t  1)K 2dtds+
Z 1
1 z
Z 1
z
K(K   1)(s+ t  1)K 2dtds
= 1  2zK
if 0:5  z  1
Pr(S > z; T > z) =
Z 1
z
Z 1
z
K(K   1)(s+ t  1)K 2dtds
= 1  2zK + (2z   1)K
Then, we have
G(z) =
8><>:2z
K ; if 0  z < 0:5
2zK   (2z   1)K ; if 0:5  z  1
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Theorem D.0.3. If ~p1;    ; ~pK independently and identically follow U(0; 1) distribution,
then the cumulative distribution function (CDF) of statistic V roP OCg is given by Case1:
r  K   r + 1.
F (z) =
8><>:2(1  F (r   1; K; z)); if 0  z < 0:51 Pr 1j=K r+1PK jh=K r+1 K!j!h!(K j h)!(1  z)j+h(2z   1)K j h; if 0:5  z  1(D.5)
(D.6)
Case2: r < K   r + 1
F (z) =
8><>:1 
Pr 1
l=0
Pr 1
m=0
K!
l!m!(K l m)!z
m+l(1  2z)K l m; if 0  z  0:5
1; if 0:5  z  1
(D.7)
Proof. Let X[r] = X[r]fX1;    ; XKg denote the rth order statistic of K random variables
X1;    ; XK ,Under the null hypothesis,~pk , 1  ~pk and pk all have the U(0; 1) distribution. It
follows that
QropL = X[r]f~p1; ~p2;    ; ~pKg (D.8)
QropR = X[r]f1  ~p1; 1  ~p2;    ; 1  ~pKg (D.9)
and
QropU = X[r]fp1; p2;    ; pKg (D.10)
All have the Beta(r;K   r + 1) distribution under H0.
Then, the one-sided test statistic is dened as
QropC = min(Q
rop
L ; Q
rop
R ) (D.11)
Let ~p[r] denote the rth order statistics of ~p1;    ; ~pK . Then, we have
S = QropL = ~p[r]
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and
T = QropR = 1  ~p[K r+1]
Therefore, we have
X = ~p[K r+1] = 1  T
and
Y = ~p[r] = S
Case1: r > K   r + 1. Then, by theorem, we have the joint pdf of X and Y :
g(x; y) =
xK r(y   x)2r K 2(1  y)K r
B(r;K   r + 1)B(K   r + 1; 2r  K   1)
if 0 < x < y < 1, and zero otherwise, and B(:; :) is the Beta function. The Jacobian is J=-1,
so the joint pdf of S and T is given by
f(s; t) =
(1  t)K r(s+ t  1)2r K 2(1  s)K r
B(r;K   r + 1)B(K   r + 1; 2r  K   1) (D.12)
If s+ t  1 > 0, 0 < s < 1 and 0 < t < 1, and zero otherwise.
Thus, we have
G(z) = Pr(QrCop  z)
= Pr(min(S; T )  z)
= 1  Pr(min(S; T ) > z)
= 1  Pr(S > z; T > z)
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if 0 < z < 0:5
Pr(S > z; T > z) =
Z 1 z
z
Z 1
1 s
(1  t)K r(s+ t  1)2r K 2(1  s)K r
B(r;K   r + 1)B(K   r + 1; 2r  K   1)dtds
+
Z 1
1 z
Z 1
z
(1  t)K r(s+ t  1)2r K 2(1  s)K r
B(r;K   r + 1)B(K   r + 1; 2r  K   1)dtds
=
R 1 z
z
(1  s)K rsr 1ds
B(r;K   r + 1) + (F (r   1; K; z)  F (K   r;K; z))
= (F (r   1; K; z)  F (r   1; K; 1  z)) + (F (r   1; K; z)  F (K   r;K; z))
= 2F (r   1; K; z)  F (r   1; K; 1  z)  F (K   r;K; z)
= 2F (r   1; K; z)  1
,whre F (x;K; p) = Pr(X  x) is the CDF of random variableX from a binomial distribution
with the sample size K and the "probability of success",p
if 0:5  z  1
Pr(S > z; T > z) =
Z 1
z
Z 1
z
(1  t)K r(s+ t  1)2r K 2(1  s)K r
B(r;K   r + 1)B(K   r + 1; 2r  K   1)dtds
=
1
B(r;K   r + 1)
Z 1
z
(1  s)K rsr 1I 1 z
s
(K   r + 1; 2r   k   2)ds
=
1
B(r;K   r + 1)
r 1X
j=K r+1
(r   1)!
j!(r   1  j)!(1  z)
j
Z 1
z
(1  s)K r(s  1 + z)r 1 jds
=
1
B(r;K   r + 1)
r 1X
j=K r+1
(r   1)!
j!(r   1  j)!(1  z)
jzK j
Z 1 z
z
0
vK r(1  v)r 1 jdv
=
r 1X
j=K r+1
K jX
h=K r+1
K!
j!h!(K   j   h)!(1  z)
j+h(2z   1)K j h
Then, we have
G(z) =
8><>:2(1  F (r   1; K; z)); if 0  z < 0:51 Pr 1j=K r+1PK jh=K r+1 K!j!h!(K j h)!(1  z)j+h(2z   1)K j h; if 0:5  z  1
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Case2: r < K   r + 1, similarly, we have
g(x; y) =
xr 1(x  y)K 2r(1  x)r 1
B(r;K   r + 1)B(K   2r + 1; r)
and
g(s; t) =
sr 1(1  s  t)K 2r(t)r 1
B(r;K   r + 1)B(K   2r + 1; r)
if 1  t  s > 0, 0 < t < 1 and 0 < s < 1, and zero otherwise.
Then, if 0  z < 0:5, we have
Pr(S > z; T > z) =
Z 1 z
z
Z 1 s
z
sr 1(1  s  t)K 2rtr 1
B(r;K   r + 1)B(K   2r + 1; r)dtds
=
K rX
j=K 2r+1
r+jX
h=j+1
K!
(K   r   j)!h!(r + j   h)!z
K h(1  2z)h
if 0:5  z < 1, we have Pr(S > z; T > z) = 0
G(z) =
8><>:1 
PK r
j=K 2r+1
Pr+j
h=j+1
K!
(K r j)!h!(r+j h)!z
K h(1  2z)h; if 0  z  0:5
1; if 0:5  z  1
=
8><>:1 
Pr 1
l=0
Pr 1
m=0
K!
l!m!(K l m)!z
m+l(1  2z)K l m; if 0  z  0:5
1; if 0:5  z  1
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APPENDIX E
TABLE OF SIMULATIONS
99
Figure E1: Simulation scheme of three correlation structures in Scenario I, II and III. (X:
disease state; Y: gene expression; Z: clinical variables)
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APPENDIX F
TEN MDD RELATED GENES
101
Figure F1: The direction of covariates eect in RIM minP models for 10 MDD related genes
from literature.
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